



## Clinical trial results:

### A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

#### Summary

|                          |                  |
|--------------------------|------------------|
| EudraCT number           | 2021-006329-23   |
| Trial protocol           | ES               |
| Global end of trial date | 28 February 2024 |

#### Results information

|                                |                  |
|--------------------------------|------------------|
| Result version number          | v1 (current)     |
| This version publication date  | 20 February 2025 |
| First version publication date | 20 February 2025 |

#### Trial information

##### Trial identification

|                       |                |
|-----------------------|----------------|
| Sponsor protocol code | INCB 54707-206 |
|-----------------------|----------------|

##### Additional study identifiers

|                                    |   |
|------------------------------------|---|
| ISRCTN number                      | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN)   | - |

Notes:

##### Sponsors

|                              |                                                                      |
|------------------------------|----------------------------------------------------------------------|
| Sponsor organisation name    | Incyte Corporation                                                   |
| Sponsor organisation address | 1801 Augustine Cutoff Drive, Wilmington, United States, 19803        |
| Public contact               | Study Director, Incyte Corporation, 1 8554633463, medinfo@incyte.com |
| Scientific contact           | Study Director, Incyte Corporation, 1 8554633463, medinfo@incyte.com |

Notes:

##### Paediatric regulatory details

|                                                                      |    |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|                                                      |                  |
|------------------------------------------------------|------------------|
| Analysis stage                                       | Final            |
| Date of interim/final analysis                       | 28 February 2024 |
| Is this the analysis of the primary completion data? | No               |
| Global end of trial reached?                         | Yes              |
| Global end of trial date                             | 28 February 2024 |
| Was the trial ended prematurely?                     | No               |

Notes:

## General information about the trial

Main objective of the trial:

The purpose of this study was to evaluate the efficacy and safety of povorcitinib in participants with prurigo nodularis over a 16-week double-blind, placebo-controlled treatment period, followed by a 24-week, single-blind extension period.

Protection of trial subjects:

This study was performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and was conducted in adherence to the study Protocol, applicable Good Clinical Practices, and applicable laws and country-specific regulations in which the study was conducted.

Background therapy: -

Evidence for comparator: -

|                                                           |                  |
|-----------------------------------------------------------|------------------|
| Actual start date of recruitment                          | 04 November 2021 |
| Long term follow-up planned                               | No               |
| Independent data monitoring committee (IDMC) involvement? | No               |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                   |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | Canada: 15        |
| Country: Number of subjects enrolled | Germany: 31       |
| Country: Number of subjects enrolled | Spain: 13         |
| Country: Number of subjects enrolled | Poland: 11        |
| Country: Number of subjects enrolled | Puerto Rico: 1    |
| Country: Number of subjects enrolled | United States: 75 |
| Worldwide total number of subjects   | 146               |
| EEA total number of subjects         | 55                |

Notes:

### Subjects enrolled per age group

|                                           |   |
|-------------------------------------------|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days)                      | 0 |
| Infants and toddlers (28 days-23 months)  | 0 |
| Children (2-11 years)                     | 0 |

|                           |     |
|---------------------------|-----|
| Adolescents (12-17 years) | 0   |
| Adults (18-64 years)      | 108 |
| From 65 to 84 years       | 38  |
| 85 years and over         | 0   |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The study was conducted across 40 sites in Canada, Germany, Spain, Poland, Puerto Rico, and the United States.

### Period 1

|                              |                                                        |
|------------------------------|--------------------------------------------------------|
| Period 1 title               | 16-week Placebo-controlled (PC) Period                 |
| Is this the baseline period? | Yes                                                    |
| Allocation method            | Randomised - controlled                                |
| Blinding used                | Double blind                                           |
| Roles blinded                | Subject, Investigator, Monitor, Data analyst, Assessor |

### Arms

|                              |         |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes     |
| <b>Arm title</b>             | Placebo |

Arm description:

On Day 1, participants were randomized to receive matching placebo once daily (QD) and stratified by Investigator's Global Assessment (IGA) score (3 versus 4). Participants received blinded study drug through Week 16.

|                                        |              |
|----------------------------------------|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | Placebo      |
| Investigational medicinal product code |              |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

Matching placebo tablets administered orally once daily

|                  |                    |
|------------------|--------------------|
| <b>Arm title</b> | Povorcitinib 15 mg |
|------------------|--------------------|

Arm description:

On Day 1, participants were randomized to receive povorcitinib 15 milligrams (mg) QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16.

|                                        |              |
|----------------------------------------|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | povorcitinib |
| Investigational medicinal product code |              |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

15 mg tablets administered orally once daily

|                  |                    |
|------------------|--------------------|
| <b>Arm title</b> | Povorcitinib 45 mg |
|------------------|--------------------|

Arm description:

On Day 1, participants were randomized to receive povorcitinib 45 mg QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16.

|          |              |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

|                                              |                    |
|----------------------------------------------|--------------------|
| Investigational medicinal product name       | povorcitinib       |
| Investigational medicinal product code       |                    |
| Other name                                   |                    |
| Pharmaceutical forms                         | Tablet             |
| Routes of administration                     | Oral use           |
| Dosage and administration details:           |                    |
| 15 mg tablets administered orally once daily |                    |
| <b>Arm title</b>                             | Povorcitinib 75 mg |

Arm description:

On Day 1, participants were randomized to receive povorcitinib 75 mg QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16.

|                                        |              |
|----------------------------------------|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | povorcitinib |
| Investigational medicinal product code |              |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

15 mg tablets administered orally once daily

| <b>Number of subjects in period 1</b> | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg |
|---------------------------------------|---------|--------------------|--------------------|
| Started                               | 37      | 36                 | 36                 |
| Completed                             | 32      | 29                 | 31                 |
| Not completed                         | 5       | 7                  | 5                  |
| Adverse event, serious fatal          | -       | 1                  | -                  |
| Consent withdrawn by subject          | 2       | 4                  | 2                  |
| Adverse event, non-fatal              | 1       | 1                  | 1                  |
| Sponsor Decision                      | -       | -                  | -                  |
| Lost to follow-up                     | -       | -                  | 1                  |
| Lack of efficacy                      | 1       | -                  | -                  |
| Protocol deviation                    | 1       | 1                  | 1                  |

| <b>Number of subjects in period 1</b> | Povorcitinib 75 mg |
|---------------------------------------|--------------------|
| Started                               | 37                 |
| Completed                             | 33                 |
| Not completed                         | 4                  |
| Adverse event, serious fatal          | -                  |
| Consent withdrawn by subject          | 2                  |
| Adverse event, non-fatal              | -                  |
| Sponsor Decision                      | 1                  |
| Lost to follow-up                     | -                  |
| Lack of efficacy                      | -                  |
| Protocol deviation                    | 1                  |

## Period 2

|                              |                             |
|------------------------------|-----------------------------|
| Period 2 title               | 24-week Extension Period    |
| Is this the baseline period? | No                          |
| Allocation method            | Non-randomised - controlled |
| Blinding used                | Single blind                |
| Roles blinded                | Subject                     |

## Arms

|                              |                               |
|------------------------------|-------------------------------|
| Are arms mutually exclusive? | Yes                           |
| <b>Arm title</b>             | Placebo to povorcitinib 45 mg |

### Arm description:

Participants who received placebo during the 16-week placebo-controlled period and were classified as responders at Week 16 received povorcitinib 45 mg QD for 24 weeks in the extension period. Responders were defined as participants who had a  $\geq 4$ -point decrease in Itch Numerical Rating Scale (NRS) score and Investigator's Global Assessment-Treatment Success (IGA-TS) who did not receive rescue therapy during the placebo-controlled period.

|                                        |              |
|----------------------------------------|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | povorcitinib |
| Investigational medicinal product code |              |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

### Dosage and administration details:

15 mg tablets administered orally once daily

|                  |                             |
|------------------|-----------------------------|
| <b>Arm title</b> | Povorcitinib 15 mg to 45 mg |
|------------------|-----------------------------|

### Arm description:

Participants who received povorcitinib 15 mg during the 16-week placebo-controlled period and were classified as responders at Week 16 received povorcitinib 45 mg QD for 24 weeks in the extension period. Responders were defined as participants who had a  $\geq 4$ -point decrease in Itch NRS score and IGA-TS who did not receive rescue therapy during the placebo-controlled period.

|                                        |              |
|----------------------------------------|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | povorcitinib |
| Investigational medicinal product code |              |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

### Dosage and administration details:

15 mg tablets administered orally once daily

|                  |                    |
|------------------|--------------------|
| <b>Arm title</b> | Povorcitinib 45 mg |
|------------------|--------------------|

### Arm description:

Participants who received povorcitinib 45 mg during the 16-week placebo-controlled period and were classified as responders at Week 16 received povorcitinib 45 mg QD for an additional 24 weeks in the extension period. Responders were defined as participants who had a  $\geq 4$ -point decrease in Itch NRS

score and IGA-TS who did not receive rescue therapy during the placebo-controlled period.

|                                              |                             |
|----------------------------------------------|-----------------------------|
| Arm type                                     | Experimental                |
| Investigational medicinal product name       | povorcitinib                |
| Investigational medicinal product code       |                             |
| Other name                                   |                             |
| Pharmaceutical forms                         | Tablet                      |
| Routes of administration                     | Oral use                    |
| Dosage and administration details:           |                             |
| 15 mg tablets administered orally once daily |                             |
| <b>Arm title</b>                             | Povorcitinib 75 mg to 45 mg |

Arm description:

Participants who received povorcitinib 75 mg during the 16-week placebo-controlled period and were classified as responders at Week 16 received povorcitinib 45 mg QD for 24 weeks in the extension period. Responders were defined as participants who had a  $\geq 4$ -point decrease in Itch NRS score and IGA-TS who did not receive rescue therapy during the placebo-controlled period.

|                                              |                               |
|----------------------------------------------|-------------------------------|
| Arm type                                     | Experimental                  |
| Investigational medicinal product name       | povorcitinib                  |
| Investigational medicinal product code       |                               |
| Other name                                   |                               |
| Pharmaceutical forms                         | Tablet                        |
| Routes of administration                     | Oral use                      |
| Dosage and administration details:           |                               |
| 15 mg tablets administered orally once daily |                               |
| <b>Arm title</b>                             | Placebo to povorcitinib 75 mg |

Arm description:

Participants who received placebo during the 16-week placebo-controlled period and were classified as non-responders at Week 16 received povorcitinib 75 mg QD for 24 weeks in the extension period. Non-responders were defined as participants not meeting the definition of a responder.

|                                              |                             |
|----------------------------------------------|-----------------------------|
| Arm type                                     | Experimental                |
| Investigational medicinal product name       | povorcitinib                |
| Investigational medicinal product code       |                             |
| Other name                                   |                             |
| Pharmaceutical forms                         | Tablet                      |
| Routes of administration                     | Oral use                    |
| Dosage and administration details:           |                             |
| 15 mg tablets administered orally once daily |                             |
| <b>Arm title</b>                             | Povorcitinib 15 mg to 75 mg |

Arm description:

Participants who received povorcitinib 15 mg during the 16-week placebo-controlled period and were classified as non-responders at Week 16 received povorcitinib 75 mg QD for 24 weeks in the extension period. Non-responders were defined as participants not meeting the definition of a responder.

|                                              |                             |
|----------------------------------------------|-----------------------------|
| Arm type                                     | Experimental                |
| Investigational medicinal product name       | povorcitinib                |
| Investigational medicinal product code       |                             |
| Other name                                   |                             |
| Pharmaceutical forms                         | Tablet                      |
| Routes of administration                     | Oral use                    |
| Dosage and administration details:           |                             |
| 15 mg tablets administered orally once daily |                             |
| <b>Arm title</b>                             | Povorcitinib 45 mg to 75 mg |

Arm description:

Participants who received povorcitinib 45 mg during the 16-week placebo-controlled period and were classified as non-responders at Week 16 received povorcitinib 75 mg QD for 24 weeks in the extension

period. Non-responders were defined as participants not meeting the definition of a responder.

|                                              |                    |
|----------------------------------------------|--------------------|
| Arm type                                     | Experimental       |
| Investigational medicinal product name       | povorcitinib       |
| Investigational medicinal product code       |                    |
| Other name                                   |                    |
| Pharmaceutical forms                         | Tablet             |
| Routes of administration                     | Oral use           |
| Dosage and administration details:           |                    |
| 15 mg tablets administered orally once daily |                    |
| <b>Arm title</b>                             | Povorcitinib 75 mg |

Arm description:

Participants who received povorcitinib 75 mg during the 16-week placebo-controlled period and were classified as non-responders at Week 16 received povorcitinib 75 mg QD for an additional 24 weeks in the extension period. Non-responders were defined as participants not meeting the definition of a responder.

|                                        |              |
|----------------------------------------|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | povorcitinib |
| Investigational medicinal product code |              |
| Other name                             |              |
| Pharmaceutical forms                   | Tablet       |
| Routes of administration               | Oral use     |

Dosage and administration details:

15 mg tablets administered orally once daily

| <b>Number of subjects in period 2<sup>[1]</sup></b> | Placebo to povorcitinib 45 mg | Povorcitinib 15 mg to 45 mg | Povorcitinib 45 mg |
|-----------------------------------------------------|-------------------------------|-----------------------------|--------------------|
| Started                                             | 1                             | 4                           | 8                  |
| Completed                                           | 1                             | 4                           | 7                  |
| Not completed                                       | 0                             | 0                           | 1                  |
| Site Closure                                        | -                             | -                           | -                  |
| Consent withdrawn by subject                        | -                             | -                           | -                  |
| Adverse event, non-fatal                            | -                             | -                           | -                  |
| Sponsor Decision                                    | -                             | -                           | -                  |
| Lost to follow-up                                   | -                             | -                           | 1                  |
| Lack of efficacy                                    | -                             | -                           | -                  |

| <b>Number of subjects in period 2<sup>[1]</sup></b> | Povorcitinib 75 mg to 45 mg | Placebo to povorcitinib 75 mg | Povorcitinib 15 mg to 75 mg |
|-----------------------------------------------------|-----------------------------|-------------------------------|-----------------------------|
| Started                                             | 15                          | 30                            | 25                          |
| Completed                                           | 12                          | 25                            | 22                          |
| Not completed                                       | 3                           | 5                             | 3                           |
| Site Closure                                        | -                           | 1                             | -                           |
| Consent withdrawn by subject                        | -                           | 1                             | 2                           |
| Adverse event, non-fatal                            | 2                           | 2                             | -                           |
| Sponsor Decision                                    | 1                           | -                             | -                           |

|                   |   |   |   |
|-------------------|---|---|---|
| Lost to follow-up | - | 1 | 1 |
| Lack of efficacy  | - | - | - |

| <b>Number of subjects in period 2<sup>[1]</sup></b> | Povorcitinib 45 mg to 75 mg | Povorcitinib 75 mg |
|-----------------------------------------------------|-----------------------------|--------------------|
| Started                                             | 23                          | 18                 |
| Completed                                           | 18                          | 13                 |
| Not completed                                       | 5                           | 5                  |
| Site Closure                                        | -                           | 1                  |
| Consent withdrawn by subject                        | 2                           | 1                  |
| Adverse event, non-fatal                            | 1                           | 3                  |
| Sponsor Decision                                    | -                           | -                  |
| Lost to follow-up                                   | -                           | -                  |
| Lack of efficacy                                    | 2                           | -                  |

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Not all participants who completed the Placebo-controlled Period started the Extension Period.

## Baseline characteristics

### Reporting groups

|                                                                                                                                                                                                                           |                    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Reporting group title                                                                                                                                                                                                     | Placebo            |
| Reporting group description:                                                                                                                                                                                              |                    |
| On Day 1, participants were randomized to receive matching placebo once daily (QD) and stratified by Investigator's Global Assessment (IGA) score (3 versus 4). Participants received blinded study drug through Week 16. |                    |
| Reporting group title                                                                                                                                                                                                     | Povorcitinib 15 mg |
| Reporting group description:                                                                                                                                                                                              |                    |
| On Day 1, participants were randomized to receive povorcitinib 15 milligrams (mg) QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16.                                  |                    |
| Reporting group title                                                                                                                                                                                                     | Povorcitinib 45 mg |
| Reporting group description:                                                                                                                                                                                              |                    |
| On Day 1, participants were randomized to receive povorcitinib 45 mg QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16.                                               |                    |
| Reporting group title                                                                                                                                                                                                     | Povorcitinib 75 mg |
| Reporting group description:                                                                                                                                                                                              |                    |
| On Day 1, participants were randomized to receive povorcitinib 75 mg QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16.                                               |                    |

| Reporting group values                             | Placebo | Povorcitinib 15 mg | Povorcitinib 45 mg |
|----------------------------------------------------|---------|--------------------|--------------------|
| Number of subjects                                 | 37      | 36                 | 36                 |
| Age categorical                                    |         |                    |                    |
| Units: Subjects                                    |         |                    |                    |
| In utero                                           | 0       | 0                  | 0                  |
| Preterm newborn infants (gestational age < 37 wks) | 0       | 0                  | 0                  |
| Newborns (0-27 days)                               | 0       | 0                  | 0                  |
| Infants and toddlers (28 days-23 months)           | 0       | 0                  | 0                  |
| Children (2-11 years)                              | 0       | 0                  | 0                  |
| Adolescents (12-17 years)                          | 0       | 0                  | 0                  |
| Adults (18-64 years)                               | 29      | 27                 | 23                 |
| From 65-84 years                                   | 8       | 9                  | 13                 |
| 85 years and over                                  | 0       | 0                  | 0                  |
| Age Continuous                                     |         |                    |                    |
| Units: years                                       |         |                    |                    |
| arithmetic mean                                    | 52.9    | 56.0               | 55.6               |
| standard deviation                                 | ± 12.32 | ± 12.92            | ± 15.25            |
| Sex: Female, Male                                  |         |                    |                    |
| Units: participants                                |         |                    |                    |
| Female                                             | 22      | 24                 | 27                 |
| Male                                               | 15      | 12                 | 9                  |
| Race/Ethnicity, Customized                         |         |                    |                    |
| Units: Subjects                                    |         |                    |                    |
| White/Caucasian                                    | 33      | 31                 | 27                 |
| Black/African-American                             | 3       | 3                  | 5                  |
| Asian                                              | 0       | 2                  | 4                  |
| American-Indian/Alaska Native                      | 0       | 0                  | 0                  |
| Unknown                                            | 1       | 0                  | 0                  |

|                         |    |    |    |
|-------------------------|----|----|----|
| Ethnicity (NIH/OMB)     |    |    |    |
| Units: Subjects         |    |    |    |
| Hispanic or Latino      | 7  | 3  | 3  |
| Not Hispanic or Latino  | 30 | 32 | 33 |
| Unknown or Not Reported | 0  | 1  | 0  |

| <b>Reporting group values</b>                         | Povorcitinib 75 mg | Total |  |
|-------------------------------------------------------|--------------------|-------|--|
| Number of subjects                                    | 37                 | 146   |  |
| Age categorical                                       |                    |       |  |
| Units: Subjects                                       |                    |       |  |
| In utero                                              | 0                  | 0     |  |
| Preterm newborn infants<br>(gestational age < 37 wks) | 0                  | 0     |  |
| Newborns (0-27 days)                                  | 0                  | 0     |  |
| Infants and toddlers (28 days-23 months)              | 0                  | 0     |  |
| Children (2-11 years)                                 | 0                  | 0     |  |
| Adolescents (12-17 years)                             | 0                  | 0     |  |
| Adults (18-64 years)                                  | 29                 | 108   |  |
| From 65-84 years                                      | 8                  | 38    |  |
| 85 years and over                                     | 0                  | 0     |  |
| Age Continuous                                        |                    |       |  |
| Units: years                                          |                    |       |  |
| arithmetic mean                                       | 55.9               |       |  |
| standard deviation                                    | ± 10.18            | -     |  |
| Sex: Female, Male                                     |                    |       |  |
| Units: participants                                   |                    |       |  |
| Female                                                | 23                 | 96    |  |
| Male                                                  | 14                 | 50    |  |
| Race/Ethnicity, Customized                            |                    |       |  |
| Units: Subjects                                       |                    |       |  |
| White/Caucasian                                       | 30                 | 121   |  |
| Black/African-American                                | 5                  | 16    |  |
| Asian                                                 | 1                  | 7     |  |
| American-Indian/Alaska Native                         | 1                  | 1     |  |
| Unknown                                               | 0                  | 1     |  |
| Ethnicity (NIH/OMB)                                   |                    |       |  |
| Units: Subjects                                       |                    |       |  |
| Hispanic or Latino                                    | 3                  | 16    |  |
| Not Hispanic or Latino                                | 33                 | 128   |  |
| Unknown or Not Reported                               | 1                  | 2     |  |

## End points

### End points reporting groups

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Placebo                       |
| Reporting group description:<br>On Day 1, participants were randomized to receive matching placebo once daily (QD) and stratified by Investigator's Global Assessment (IGA) score (3 versus 4). Participants received blinded study drug through Week 16.                                                                                                                                                                                                                                       |                               |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Povorcitinib 15 mg            |
| Reporting group description:<br>On Day 1, participants were randomized to receive povorcitinib 15 milligrams (mg) QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16.                                                                                                                                                                                                                                                                        |                               |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Povorcitinib 45 mg            |
| Reporting group description:<br>On Day 1, participants were randomized to receive povorcitinib 45 mg QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16.                                                                                                                                                                                                                                                                                     |                               |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Povorcitinib 75 mg            |
| Reporting group description:<br>On Day 1, participants were randomized to receive povorcitinib 75 mg QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16.                                                                                                                                                                                                                                                                                     |                               |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Placebo to povorcitinib 45 mg |
| Reporting group description:<br>Participants who received placebo during the 16-week placebo-controlled period and were classified as responders at Week 16 received povorcitinib 45 mg QD for 24 weeks in the extension period. Responders were defined as participants who had a $\geq 4$ -point decrease in Itch Numerical Rating Scale (NRS) score and Investigator's Global Assessment-Treatment Success (IGA-TS) who did not receive rescue therapy during the placebo-controlled period. |                               |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Povorcitinib 15 mg to 45 mg   |
| Reporting group description:<br>Participants who received povorcitinib 15 mg during the 16-week placebo-controlled period and were classified as responders at Week 16 received povorcitinib 45 mg QD for 24 weeks in the extension period. Responders were defined as participants who had a $\geq 4$ -point decrease in Itch NRS score and IGA-TS who did not receive rescue therapy during the placebo-controlled period.                                                                    |                               |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Povorcitinib 45 mg            |
| Reporting group description:<br>Participants who received povorcitinib 45 mg during the 16-week placebo-controlled period and were classified as responders at Week 16 received povorcitinib 45 mg QD for an additional 24 weeks in the extension period. Responders were defined as participants who had a $\geq 4$ -point decrease in Itch NRS score and IGA-TS who did not receive rescue therapy during the placebo-controlled period.                                                      |                               |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Povorcitinib 75 mg to 45 mg   |
| Reporting group description:<br>Participants who received povorcitinib 75 mg during the 16-week placebo-controlled period and were classified as responders at Week 16 received povorcitinib 45 mg QD for 24 weeks in the extension period. Responders were defined as participants who had a $\geq 4$ -point decrease in Itch NRS score and IGA-TS who did not receive rescue therapy during the placebo-controlled period.                                                                    |                               |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Placebo to povorcitinib 75 mg |
| Reporting group description:<br>Participants who received placebo during the 16-week placebo-controlled period and were classified as non-responders at Week 16 received povorcitinib 75 mg QD for 24 weeks in the extension period. Non-responders were defined as participants not meeting the definition of a responder.                                                                                                                                                                     |                               |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Povorcitinib 15 mg to 75 mg   |
| Reporting group description:<br>Participants who received povorcitinib 15 mg during the 16-week placebo-controlled period and were classified as non-responders at Week 16 received povorcitinib 75 mg QD for 24 weeks in the extension period. Non-responders were defined as participants not meeting the definition of a responder.                                                                                                                                                          |                               |
| Reporting group title                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Povorcitinib 45 mg to 75 mg   |

**Reporting group description:**

Participants who received povorcitinib 45 mg during the 16-week placebo-controlled period and were classified as non-responders at Week 16 received povorcitinib 75 mg QD for 24 weeks in the extension period. Non-responders were defined as participants not meeting the definition of a responder.

|                       |                    |
|-----------------------|--------------------|
| Reporting group title | Povorcitinib 75 mg |
|-----------------------|--------------------|

**Reporting group description:**

Participants who received povorcitinib 75 mg during the 16-week placebo-controlled period and were classified as non-responders at Week 16 received povorcitinib 75 mg QD for an additional 24 weeks in the extension period. Non-responders were defined as participants not meeting the definition of a responder.

### Primary: Percentage of participants achieving $\geq 4$ -point improvement in Itch Numerical Rating Scale (NRS) score at Week 16

|                 |                                                                                                                        |
|-----------------|------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of participants achieving $\geq 4$ -point improvement in Itch Numerical Rating Scale (NRS) score at Week 16 |
|-----------------|------------------------------------------------------------------------------------------------------------------------|

**End point description:**

Each evening, the participants assessed their worst level of itch during the past 24 hours on a scale of 0 (no itch) to 10 (worst itch imaginable). The Baseline Itch NRS score was determined by averaging the 7 daily Itch NRS scores before Day 1 (i.e., Day -7 to Day -1). If  $\geq 4$  of the 7 days of the daily Itch NRS scores were missing prior to Day 1, then the Baseline Itch NRS score was set to "missing." The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily Itch NRS scores before the visit day. If 4 or more daily Itch NRS scores out of the 7 days before the visit day were missing, the Itch NRS score at the visit was set to missing. Analysis was conducted in members of the Intent-to-Treat (ITT) Population, comprised of all randomized participants. Missing post-Baseline values and rescue therapy recipients for all subsequent visits after the initiation date of rescue therapy were imputed as nonresponders.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

**End point timeframe:**

Baseline; Week 16

| End point values                  | Placebo           | Povorcitinib 15 mg  | Povorcitinib 45 mg  | Povorcitinib 75 mg  |
|-----------------------------------|-------------------|---------------------|---------------------|---------------------|
| Subject group type                | Reporting group   | Reporting group     | Reporting group     | Reporting group     |
| Number of subjects analysed       | 37 <sup>[1]</sup> | 36 <sup>[2]</sup>   | 36 <sup>[3]</sup>   | 37 <sup>[4]</sup>   |
| Units: percentage of participants |                   |                     |                     |                     |
| number (confidence interval 95%)  | 8.1 (1.7 to 21.9) | 36.1 (20.8 to 53.8) | 44.4 (27.9 to 61.9) | 56.8 (39.5 to 72.9) |

**Notes:**

[1] - ITT Population. The 95% confidence interval was based on the Clopper-Pearson exact method.

[2] - ITT Population. The 95% confidence interval was based on the Clopper-Pearson exact method.

[3] - ITT Population. The 95% confidence interval was based on the Clopper-Pearson exact method.

[4] - ITT Population. The 95% confidence interval was based on the Clopper-Pearson exact method.

**Statistical analyses**

|                                   |                                          |
|-----------------------------------|------------------------------------------|
| <b>Statistical analysis title</b> | Placebo:15 mg; Exact logistic regression |
| Comparison groups                 | Placebo v Povorcitinib 15 mg             |

|                                         |                         |
|-----------------------------------------|-------------------------|
| Number of subjects included in analysis | 73                      |
| Analysis specification                  | Pre-specified           |
| Analysis type                           |                         |
| P-value                                 | = 0.0061 <sup>[5]</sup> |
| Method                                  | Regression, Logistic    |
| Parameter estimate                      | Odds ratio (OR)         |
| Point estimate                          | 7.1                     |
| Confidence interval                     |                         |
| level                                   | 95 %                    |
| sides                                   | 2-sided                 |
| lower limit                             | 1.6                     |
| upper limit                             | 45.4                    |

Notes:

[5] - Exact Logistic regression: (response at Week 16 = treatment + stratification factor [Day 1 Investigator's Global Assessment score (3 or 4)])

|                                         |                                          |
|-----------------------------------------|------------------------------------------|
| <b>Statistical analysis title</b>       | Placebo:75 mg; Exact logistic regression |
| Comparison groups                       | Placebo v Povorcitinib 75 mg             |
| Number of subjects included in analysis | 74                                       |
| Analysis specification                  | Pre-specified                            |
| Analysis type                           |                                          |
| P-value                                 | < 0.0001 <sup>[6]</sup>                  |
| Method                                  | Regression, Logistic                     |
| Parameter estimate                      | Odds ratio (OR)                          |
| Point estimate                          | 16.8                                     |
| Confidence interval                     |                                          |
| level                                   | 95 %                                     |
| sides                                   | 2-sided                                  |
| lower limit                             | 3.9                                      |
| upper limit                             | 107.5                                    |

Notes:

[6] - Exact Logistic regression: (response at Week 16 = treatment + stratification factor [Day 1 Investigator's Global Assessment score (3 or 4)])

|                                         |                                          |
|-----------------------------------------|------------------------------------------|
| <b>Statistical analysis title</b>       | Placebo:45 mg; Exact logistic regression |
| Comparison groups                       | Placebo v Povorcitinib 45 mg             |
| Number of subjects included in analysis | 73                                       |
| Analysis specification                  | Pre-specified                            |
| Analysis type                           |                                          |
| P-value                                 | = 0.0005 <sup>[7]</sup>                  |
| Method                                  | Regression, Logistic                     |
| Parameter estimate                      | Odds ratio (OR)                          |
| Point estimate                          | 10.2                                     |
| Confidence interval                     |                                          |
| level                                   | 95 %                                     |
| sides                                   | 2-sided                                  |
| lower limit                             | 2.3                                      |
| upper limit                             | 65.6                                     |

Notes:

[7] - Exact Logistic regression: (response at Week 16 = treatment + stratification factor [Day 1 Investigator's Global Assessment score (3 or 4)])

## Secondary: Percentage of participants achieving Investigator's Global Assessment-

**Treatment Success (IGA-TS) (IGA score of 0 or 1 with a  $\geq 2$ -grade improvement from Baseline) at Week 16**

|                 |                                                                                                                                                                                    |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of participants achieving Investigator's Global Assessment-Treatment Success (IGA-TS) (IGA score of 0 or 1 with a $\geq 2$ -grade improvement from Baseline) at Week 16 |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## End point description:

The IGA for chronic prurigo considers the number of pruriginous lesions, which includes papules, nodules, plaques, umbilicated ulcers, and ulcers, and uses them as an overall severity rating on a scale of 0 to 4. 0: clear; no pruriginous lesions (0 lesions). 1: almost clear; rare palpable pruriginous lesions (approximately 1-5 lesions). 2: mild; few palpable pruriginous lesions (approximately 6-19 lesions). 3: moderate; many palpable pruriginous lesions (approximately 20-100 lesions). 4: severe; abundant palpable pruriginous lesions (over 100 lesions). The IGA-TS is defined as an IGA score of 0 or 1 with a  $\geq 2$ -grade improvement from Baseline. Missing post-Baseline values were imputed as non-responders. The 95% confidence interval was based on the Clopper-Pearson exact method.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

## End point timeframe:

Baseline; Week 16

| End point values                  | Placebo           | Povorcitinib 15 mg | Povorcitinib 45 mg  | Povorcitinib 75 mg  |
|-----------------------------------|-------------------|--------------------|---------------------|---------------------|
| Subject group type                | Reporting group   | Reporting group    | Reporting group     | Reporting group     |
| Number of subjects analysed       | 37 <sup>[8]</sup> | 36 <sup>[9]</sup>  | 36 <sup>[10]</sup>  | 37 <sup>[11]</sup>  |
| Units: percentage of participants |                   |                    |                     |                     |
| number (confidence interval 95%)  | 5.4 (0.7 to 18.2) | 13.9 (4.7 to 29.5) | 30.6 (16.3 to 48.1) | 48.6 (31.9 to 65.6) |

## Notes:

[8] - ITT Population

[9] - ITT Population

[10] - ITT Population

[11] - ITT Population

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Time to  $\geq 4$ -point improvement from Baseline in Itch NRS score**

|                 |                                                                     |
|-----------------|---------------------------------------------------------------------|
| End point title | Time to $\geq 4$ -point improvement from Baseline in Itch NRS score |
|-----------------|---------------------------------------------------------------------|

## End point description:

Each evening, the participants assessed their worst level of itch during the past 24 hours on a scale of 0 (no itch) to 10 (worst itch imaginable). The Baseline Itch NRS score was determined by averaging the 7 daily Itch NRS scores before Day 1. If  $\geq 4$  of the 7 days of the daily Itch NRS scores were missing prior to Day 1, then the Baseline Itch NRS score was set to "missing." The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily Itch NRS scores before the visit day. If 4 or more daily Itch NRS scores out of the 7 days before the visit day were missing, the Itch NRS score at the visit was set to missing. The time to a  $\geq 4$ -point improvement from Baseline in itch NRS score was estimated using the Kaplan-Meier method. -9999, 9999=value was not estimable because too few participants achieved a  $\geq 4$ -point improvement from Baseline in itch NRS score.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

## End point timeframe:

up to 122 days

| End point values                 | Placebo              | Povorcitinib 15 mg  | Povorcitinib 45 mg  | Povorcitinib 75 mg  |
|----------------------------------|----------------------|---------------------|---------------------|---------------------|
| Subject group type               | Reporting group      | Reporting group     | Reporting group     | Reporting group     |
| Number of subjects analysed      | 36 <sup>[12]</sup>   | 35 <sup>[13]</sup>  | 34 <sup>[14]</sup>  | 36 <sup>[15]</sup>  |
| Units: days                      |                      |                     |                     |                     |
| median (confidence interval 95%) | 9999 (-9999 to 9999) | 58.0 (16.0 to 9999) | 35.0 (21.0 to 9999) | 19.0 (13.0 to 47.0) |

Notes:

[12] - ITT Population. Only participants with available data were analyzed.

[13] - ITT Population. Only participants with available data were analyzed.

[14] - ITT Population. Only participants with available data were analyzed.

[15] - ITT Population. Only participants with available data were analyzed.

## Statistical analyses

No statistical analyses for this end point

## Secondary: PC Period: Number of participants with any treatment-emergent adverse event (TEAE)

|                 |                                                                                    |
|-----------------|------------------------------------------------------------------------------------|
| End point title | PC Period: Number of participants with any treatment-emergent adverse event (TEAE) |
|-----------------|------------------------------------------------------------------------------------|

End point description:

An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug. Analysis was conducted in members of the Safety Population, comprised of all participants who received at least 1 dose of study drug. Treatment groups for this population were determined according to the actual treatment the participant received on Day 1.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to 152 days

| End point values            | Placebo            | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg |
|-----------------------------|--------------------|--------------------|--------------------|--------------------|
| Subject group type          | Reporting group    | Reporting group    | Reporting group    | Reporting group    |
| Number of subjects analysed | 37 <sup>[16]</sup> | 36 <sup>[17]</sup> | 35 <sup>[18]</sup> | 37 <sup>[19]</sup> |
| Units: participants         | 20                 | 20                 | 25                 | 28                 |

Notes:

[16] - Safety Population

[17] - Safety Population

[18] - Safety Population

[19] - Safety Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: PC Period: Number of participants with any ≥Grade 3 TEAE

|                 |                                                          |
|-----------------|----------------------------------------------------------|
| End point title | PC Period: Number of participants with any ≥Grade 3 TEAE |
|-----------------|----------------------------------------------------------|

End point description:

A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first

dose of study drug up to 30 days after the last dose of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 Grades 1 through 5. The investigator made an assessment of intensity for each AE and serious adverse event (SAE) reported during the study and assigned it to 1 of the following categories. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to 152 days

| End point values            | Placebo            | Povorcitinib 15 mg | Povorcitinib 45 mg | Povorcitinib 75 mg |
|-----------------------------|--------------------|--------------------|--------------------|--------------------|
| Subject group type          | Reporting group    | Reporting group    | Reporting group    | Reporting group    |
| Number of subjects analysed | 37 <sup>[20]</sup> | 36 <sup>[21]</sup> | 35 <sup>[22]</sup> | 37 <sup>[23]</sup> |
| Units: participants         | 0                  | 1                  | 1                  | 2                  |

Notes:

[20] - Safety Population

[21] - Safety Population

[22] - Safety Population

[23] - Safety Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Extension Period: Number of participants with any TEAE

|                 |                                                        |
|-----------------|--------------------------------------------------------|
| End point title | Extension Period: Number of participants with any TEAE |
|-----------------|--------------------------------------------------------|

End point description:

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug. Analysis was conducted in members of the Extension Evaluable Population, comprised of all participants who received at least 1 dose of povorcitinib during the Extension Period.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to 215 days

| End point values            | Placebo to povorcitinib 45 mg | Povorcitinib 15 mg to 45 mg | Povorcitinib 45 mg | Povorcitinib 75 mg to 45 mg |
|-----------------------------|-------------------------------|-----------------------------|--------------------|-----------------------------|
| Subject group type          | Reporting group               | Reporting group             | Reporting group    | Reporting group             |
| Number of subjects analysed | 1 <sup>[24]</sup>             | 4 <sup>[25]</sup>           | 8 <sup>[26]</sup>  | 15 <sup>[27]</sup>          |
| Units: participants         | 0                             | 3                           | 5                  | 7                           |

Notes:

[24] - Extension Evaluable Population

[25] - Extension Evaluable Population

[26] - Extension Evaluable Population

[27] - Extension Evaluable Population

| End point values            | Placebo to povorcitinib 75 mg | Povorcitinib 15 mg to 75 mg | Povorcitinib 45 mg to 75 mg | Povorcitinib 75 mg |
|-----------------------------|-------------------------------|-----------------------------|-----------------------------|--------------------|
| Subject group type          | Reporting group               | Reporting group             | Reporting group             | Reporting group    |
| Number of subjects analysed | 30 <sup>[28]</sup>            | 25 <sup>[29]</sup>          | 23 <sup>[30]</sup>          | 18 <sup>[31]</sup> |
| Units: participants         | 20                            | 19                          | 16                          | 13                 |

Notes:

[28] - Extension Evaluable Population

[29] - Extension Evaluable Population

[30] - Extension Evaluable Population

[31] - Extension Evaluable Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Extension Period: Number of participants with any ≥Grade 3 TEAE

|                 |                                                                 |
|-----------------|-----------------------------------------------------------------|
| End point title | Extension Period: Number of participants with any ≥Grade 3 TEAE |
|-----------------|-----------------------------------------------------------------|

End point description:

A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 Grades 1 through 5. The investigator made an assessment of intensity for each AE and serious adverse event (SAE) reported during the study and assigned it to 1 of the following categories. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to 215 days

| End point values            | Placebo to povorcitinib 45 mg | Povorcitinib 15 mg to 45 mg | Povorcitinib 45 mg | Povorcitinib 75 mg to 45 mg |
|-----------------------------|-------------------------------|-----------------------------|--------------------|-----------------------------|
| Subject group type          | Reporting group               | Reporting group             | Reporting group    | Reporting group             |
| Number of subjects analysed | 1 <sup>[32]</sup>             | 4 <sup>[33]</sup>           | 8 <sup>[34]</sup>  | 15 <sup>[35]</sup>          |
| Units: participants         | 0                             | 0                           | 0                  | 1                           |

Notes:

[32] - Extension Evaluable Population

[33] - Extension Evaluable Population

[34] - Extension Evaluable Population

[35] - Extension Evaluable Population

| End point values | Placebo to povorcitinib 75 mg | Povorcitinib 15 mg to 75 mg | Povorcitinib 45 mg to 75 mg | Povorcitinib 75 mg |
|------------------|-------------------------------|-----------------------------|-----------------------------|--------------------|
|------------------|-------------------------------|-----------------------------|-----------------------------|--------------------|

|                             | mg                 |                    |                    |                    |
|-----------------------------|--------------------|--------------------|--------------------|--------------------|
| Subject group type          | Reporting group    | Reporting group    | Reporting group    | Reporting group    |
| Number of subjects analysed | 30 <sup>[36]</sup> | 25 <sup>[37]</sup> | 23 <sup>[38]</sup> | 18 <sup>[39]</sup> |
| Units: participants         | 0                  | 1                  | 3                  | 3                  |

Notes:

[36] - Extension Evaluable Population

[37] - Extension Evaluable Population

[38] - Extension Evaluable Population

[39] - Extension Evaluable Population

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

from the time of Informed Consent Form signing until at least 30 days after the last dose of study drug (up to approximately 44 weeks)

Adverse event reporting additional description:

Adverse events were collected in members of the Safety Population, comprised of all participants who received at least 1 dose of study drug, and the Extension Evaluable Population, comprised of all participants who received at least 1 dose of povorcitinib during the Extension Period.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |    |
|--------------------|----|
| Dictionary version | 22 |
|--------------------|----|

### Reporting groups

|                       |         |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

On Day 1, participants were randomized to receive matching placebo once daily (QD) and stratified by Investigator's Global Assessment (IGA) score (3 versus 4). Participants received blinded placebo through Week 16.

|                       |                               |
|-----------------------|-------------------------------|
| Reporting group title | Placebo to povorcitinib 75 mg |
|-----------------------|-------------------------------|

Reporting group description:

On Day 1, participants were randomized to receive placebo QD and stratified by IGA score (3 versus 4). Participants received blinded placebo through Week 16. Based on a lack of efficacy response at Week 16 (not meeting the definition of a responder), these participants received povorcitinib 75 mg QD for an additional 24 weeks in the extension period.

|                       |                    |
|-----------------------|--------------------|
| Reporting group title | Povorcitinib 15 mg |
|-----------------------|--------------------|

Reporting group description:

On Day 1, participants were randomized to receive povorcitinib 15 mg QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16.

|                       |                               |
|-----------------------|-------------------------------|
| Reporting group title | Placebo to povorcitinib 45 mg |
|-----------------------|-------------------------------|

Reporting group description:

On Day 1, participants were randomized to receive placebo QD and stratified by IGA score (3 versus 4). Participants received blinded placebo through Week 16. Based on their efficacy response at Week 16 ( $\geq 4$ -point decrease in Itch Numerical Rating Scale [NRS] score and IGA-Treatment Success and no administration of rescue therapy during the placebo-controlled period), these participants received povorcitinib 45 milligrams (mg) QD for an additional 24 weeks in the extension period.

|                       |                             |
|-----------------------|-----------------------------|
| Reporting group title | Povorcitinib 15 mg to 45 mg |
|-----------------------|-----------------------------|

Reporting group description:

On Day 1, participants were randomized to receive povorcitinib 15 mg QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16. Based on their efficacy response at Week 16 ( $\geq 4$ -point decrease in Itch NRS score and IGA-Treatment Success and no administration of rescue therapy during the placebo-controlled period), these participants received povorcitinib 45 mg QD for an additional 24 weeks in the extension period.

|                       |                             |
|-----------------------|-----------------------------|
| Reporting group title | Povorcitinib 45 mg to 75 mg |
|-----------------------|-----------------------------|

Reporting group description:

On Day 1, participants were randomized to receive povorcitinib 45 mg QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16. Based on a lack of efficacy response at Week 16 (not meeting the definition of a responder), these participants received povorcitinib 75 mg QD for an additional 24 weeks in the extension period.

|                       |                             |
|-----------------------|-----------------------------|
| Reporting group title | Povorcitinib 15 mg to 75 mg |
|-----------------------|-----------------------------|

Reporting group description:

On Day 1, participants were randomized to receive povorcitinib 15 mg QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16. Based on a lack of efficacy response at Week 16 (not meeting the definition of a responder), these participants received povorcitinib 75 mg QD for an additional 24 weeks in the extension period.

|                       |                    |
|-----------------------|--------------------|
| Reporting group title | Povorcitinib 45 mg |
|-----------------------|--------------------|

Reporting group description:

Participants received povorcitinib 45 mg in both the placebo-controlled period and the treatment extension period. On Day 1, participants were randomized to receive povorcitinib 45 mg QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16. Based on their efficacy response at Week 16 ( $\geq 4$ -point decrease in Itch NRS score and IGA-TS and no administration of rescue therapy during the placebo-controlled period), these participants received povorcitinib 45 mg QD for an additional 24 weeks in the extension period.

|                       |                             |
|-----------------------|-----------------------------|
| Reporting group title | Povorcitinib 75 mg to 45 mg |
|-----------------------|-----------------------------|

Reporting group description:

On Day 1, participants were randomized to receive povorcitinib 75 mg QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16. Based on their efficacy response at Week 16 ( $\geq 4$ -point decrease in Itch NRS score and IGA-Treatment Success and no administration of rescue therapy during the placebo-controlled period), these participants received povorcitinib 45 mg QD for an additional 24 weeks in the extension period.

|                       |                    |
|-----------------------|--------------------|
| Reporting group title | Povorcitinib 75 mg |
|-----------------------|--------------------|

Reporting group description:

Participants received povorcitinib 75 mg in both the placebo-controlled period and the treatment extension period. On Day 1, participants were randomized to receive povorcitinib 75 mg QD and stratified by IGA score (3 versus 4). Participants received blinded study drug through Week 16. Based on a lack of efficacy response at Week 16 (not meeting the definition of a responder), these participants received povorcitinib 75 mg QD for an additional 24 weeks in the extension period.

| Serious adverse events                               | Placebo       | Placebo to povorcitinib 75 mg | Povorcitinib 15 mg |
|------------------------------------------------------|---------------|-------------------------------|--------------------|
| Total subjects affected by serious adverse events    |               |                               |                    |
| subjects affected / exposed                          | 0 / 6 (0.00%) | 1 / 30 (3.33%)                | 2 / 7 (28.57%)     |
| number of deaths (all causes)                        | 0             | 0                             | 1                  |
| number of deaths resulting from adverse events       | 0             | 0                             | 1                  |
| Nervous system disorders                             |               |                               |                    |
| Transient ischaemic attack                           |               |                               |                    |
| subjects affected / exposed                          | 0 / 6 (0.00%) | 0 / 30 (0.00%)                | 1 / 7 (14.29%)     |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0                         | 0 / 1              |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0                         | 0 / 0              |
| General disorders and administration site conditions |               |                               |                    |
| Death                                                |               |                               |                    |
| subjects affected / exposed                          | 0 / 6 (0.00%) | 0 / 30 (0.00%)                | 1 / 7 (14.29%)     |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0                         | 0 / 1              |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0                         | 0 / 1              |
| Gastrointestinal disorders                           |               |                               |                    |
| Abdominal pain upper                                 |               |                               |                    |
| subjects affected / exposed                          | 0 / 6 (0.00%) | 0 / 30 (0.00%)                | 0 / 7 (0.00%)      |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0                         | 0 / 0              |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0                         | 0 / 0              |
| Colitis                                              |               |                               |                    |

|                                                 |               |                |               |
|-------------------------------------------------|---------------|----------------|---------------|
| subjects affected / exposed                     | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0         |
| Respiratory, thoracic and mediastinal disorders |               |                |               |
| Nasal septum deviation                          |               |                |               |
| subjects affected / exposed                     | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0         |
| Skin and subcutaneous tissue disorders          |               |                |               |
| Hidradenitis                                    |               |                |               |
| subjects affected / exposed                     | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0         |
| Neurodermatitis                                 |               |                |               |
| subjects affected / exposed                     | 0 / 6 (0.00%) | 1 / 30 (3.33%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 1          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0         |
| Psychiatric disorders                           |               |                |               |
| Anxiety                                         |               |                |               |
| subjects affected / exposed                     | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0         |
| Musculoskeletal and connective tissue disorders |               |                |               |
| Intervertebral disc protrusion                  |               |                |               |
| subjects affected / exposed                     | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0         |
| Myopathy                                        |               |                |               |
| subjects affected / exposed                     | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0         |
| Infections and infestations                     |               |                |               |
| Appendicitis                                    |               |                |               |

|                                                 |               |                |               |
|-------------------------------------------------|---------------|----------------|---------------|
| subjects affected / exposed                     | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0         |
| COVID-19                                        |               |                |               |
| subjects affected / exposed                     | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0         |
| Erysipelas                                      |               |                |               |
| subjects affected / exposed                     | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0         |
| Mastitis                                        |               |                |               |
| subjects affected / exposed                     | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0         |
| Pneumonia                                       |               |                |               |
| subjects affected / exposed                     | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0         |
| Tooth infection                                 |               |                |               |
| subjects affected / exposed                     | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0         |

| Serious adverse events                            | Placebo to povorcitinib 45 mg | Povorcitinib 15 mg to 45 mg | Povorcitinib 45 mg to 75 mg |
|---------------------------------------------------|-------------------------------|-----------------------------|-----------------------------|
| Total subjects affected by serious adverse events |                               |                             |                             |
| subjects affected / exposed                       | 0 / 1 (0.00%)                 | 0 / 4 (0.00%)               | 5 / 23 (21.74%)             |
| number of deaths (all causes)                     | 0                             | 0                           | 0                           |
| number of deaths resulting from adverse events    | 0                             | 0                           | 0                           |
| Nervous system disorders                          |                               |                             |                             |
| Transient ischaemic attack                        |                               |                             |                             |
| subjects affected / exposed                       | 0 / 1 (0.00%)                 | 0 / 4 (0.00%)               | 0 / 23 (0.00%)              |
| occurrences causally related to treatment / all   | 0 / 0                         | 0 / 0                       | 0 / 0                       |
| deaths causally related to treatment / all        | 0 / 0                         | 0 / 0                       | 0 / 0                       |

|                                                      |               |               |                |
|------------------------------------------------------|---------------|---------------|----------------|
| General disorders and administration site conditions |               |               |                |
| Death                                                |               |               |                |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 0 / 4 (0.00%) | 0 / 23 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0         | 0 / 0          |
| Gastrointestinal disorders                           |               |               |                |
| Abdominal pain upper                                 |               |               |                |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 0 / 4 (0.00%) | 0 / 23 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0         | 0 / 0          |
| Colitis                                              |               |               |                |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 0 / 4 (0.00%) | 0 / 23 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0         | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders      |               |               |                |
| Nasal septum deviation                               |               |               |                |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 0 / 4 (0.00%) | 1 / 23 (4.35%) |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 1          |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0         | 0 / 0          |
| Skin and subcutaneous tissue disorders               |               |               |                |
| Hidradenitis                                         |               |               |                |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 0 / 4 (0.00%) | 0 / 23 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0         | 0 / 0          |
| Neurodermatitis                                      |               |               |                |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 0 / 4 (0.00%) | 0 / 23 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0         | 0 / 0          |
| Psychiatric disorders                                |               |               |                |
| Anxiety                                              |               |               |                |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 0 / 4 (0.00%) | 0 / 23 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0         | 0 / 0          |
| Musculoskeletal and connective tissue disorders      |               |               |                |

|                                                 |               |               |                |
|-------------------------------------------------|---------------|---------------|----------------|
| Intervertebral disc protrusion                  |               |               |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 4 (0.00%) | 1 / 23 (4.35%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| Myopathy                                        |               |               |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 4 (0.00%) | 0 / 23 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| Infections and infestations                     |               |               |                |
| Appendicitis                                    |               |               |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 4 (0.00%) | 2 / 23 (8.70%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 2          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| COVID-19                                        |               |               |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 4 (0.00%) | 1 / 23 (4.35%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| Erysipelas                                      |               |               |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 4 (0.00%) | 0 / 23 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| Mastitis                                        |               |               |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 4 (0.00%) | 0 / 23 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| Pneumonia                                       |               |               |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 4 (0.00%) | 0 / 23 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| Tooth infection                                 |               |               |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 4 (0.00%) | 0 / 23 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |

| <b>Serious adverse events</b>                        | Povorcitinib 15 mg<br>to 75 mg | Povorcitinib 45 mg | Povorcitinib 75 mg<br>to 45 mg |
|------------------------------------------------------|--------------------------------|--------------------|--------------------------------|
| Total subjects affected by serious adverse events    |                                |                    |                                |
| subjects affected / exposed                          | 1 / 25 (4.00%)                 | 1 / 12 (8.33%)     | 2 / 15 (13.33%)                |
| number of deaths (all causes)                        | 0                              | 0                  | 0                              |
| number of deaths resulting from adverse events       | 0                              | 0                  | 0                              |
| Nervous system disorders                             |                                |                    |                                |
| Transient ischaemic attack                           |                                |                    |                                |
| subjects affected / exposed                          | 0 / 25 (0.00%)                 | 0 / 12 (0.00%)     | 0 / 15 (0.00%)                 |
| occurrences causally related to treatment / all      | 0 / 0                          | 0 / 0              | 0 / 0                          |
| deaths causally related to treatment / all           | 0 / 0                          | 0 / 0              | 0 / 0                          |
| General disorders and administration site conditions |                                |                    |                                |
| Death                                                |                                |                    |                                |
| subjects affected / exposed                          | 0 / 25 (0.00%)                 | 0 / 12 (0.00%)     | 0 / 15 (0.00%)                 |
| occurrences causally related to treatment / all      | 0 / 0                          | 0 / 0              | 0 / 0                          |
| deaths causally related to treatment / all           | 0 / 0                          | 0 / 0              | 0 / 0                          |
| Gastrointestinal disorders                           |                                |                    |                                |
| Abdominal pain upper                                 |                                |                    |                                |
| subjects affected / exposed                          | 0 / 25 (0.00%)                 | 0 / 12 (0.00%)     | 1 / 15 (6.67%)                 |
| occurrences causally related to treatment / all      | 0 / 0                          | 0 / 0              | 0 / 1                          |
| deaths causally related to treatment / all           | 0 / 0                          | 0 / 0              | 0 / 0                          |
| Colitis                                              |                                |                    |                                |
| subjects affected / exposed                          | 0 / 25 (0.00%)                 | 0 / 12 (0.00%)     | 0 / 15 (0.00%)                 |
| occurrences causally related to treatment / all      | 0 / 0                          | 0 / 0              | 0 / 0                          |
| deaths causally related to treatment / all           | 0 / 0                          | 0 / 0              | 0 / 0                          |
| Respiratory, thoracic and mediastinal disorders      |                                |                    |                                |
| Nasal septum deviation                               |                                |                    |                                |
| subjects affected / exposed                          | 0 / 25 (0.00%)                 | 0 / 12 (0.00%)     | 0 / 15 (0.00%)                 |
| occurrences causally related to treatment / all      | 0 / 0                          | 0 / 0              | 0 / 0                          |
| deaths causally related to treatment / all           | 0 / 0                          | 0 / 0              | 0 / 0                          |
| Skin and subcutaneous tissue disorders               |                                |                    |                                |
| Hidradenitis                                         |                                |                    |                                |
| subjects affected / exposed                          | 0 / 25 (0.00%)                 | 0 / 12 (0.00%)     | 0 / 15 (0.00%)                 |
| occurrences causally related to treatment / all      | 0 / 0                          | 0 / 0              | 0 / 0                          |
| deaths causally related to treatment / all           | 0 / 0                          | 0 / 0              | 0 / 0                          |
| Neurodermatitis                                      |                                |                    |                                |

|                                                        |                |                |                |
|--------------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                            | 0 / 25 (0.00%) | 0 / 12 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all             | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Psychiatric disorders</b>                           |                |                |                |
| Anxiety                                                |                |                |                |
| subjects affected / exposed                            | 0 / 25 (0.00%) | 0 / 12 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all        | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all             | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Musculoskeletal and connective tissue disorders</b> |                |                |                |
| Intervertebral disc protrusion                         |                |                |                |
| subjects affected / exposed                            | 0 / 25 (0.00%) | 0 / 12 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all             | 0 / 0          | 0 / 0          | 0 / 0          |
| Myopathy                                               |                |                |                |
| subjects affected / exposed                            | 0 / 25 (0.00%) | 0 / 12 (0.00%) | 1 / 15 (6.67%) |
| occurrences causally related to treatment / all        | 0 / 0          | 0 / 0          | 1 / 1          |
| deaths causally related to treatment / all             | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Infections and infestations</b>                     |                |                |                |
| Appendicitis                                           |                |                |                |
| subjects affected / exposed                            | 0 / 25 (0.00%) | 0 / 12 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all             | 0 / 0          | 0 / 0          | 0 / 0          |
| COVID-19                                               |                |                |                |
| subjects affected / exposed                            | 0 / 25 (0.00%) | 0 / 12 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all             | 0 / 0          | 0 / 0          | 0 / 0          |
| Erysipelas                                             |                |                |                |
| subjects affected / exposed                            | 0 / 25 (0.00%) | 0 / 12 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all             | 0 / 0          | 0 / 0          | 0 / 0          |
| Mastitis                                               |                |                |                |
| subjects affected / exposed                            | 0 / 25 (0.00%) | 0 / 12 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all             | 0 / 0          | 0 / 0          | 0 / 0          |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| Pneumonia                                       |                |                |                |
| subjects affected / exposed                     | 1 / 25 (4.00%) | 0 / 12 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Tooth infection                                 |                |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%) | 1 / 12 (8.33%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

|                                                      |                    |  |  |
|------------------------------------------------------|--------------------|--|--|
| <b>Serious adverse events</b>                        | Povorcitinib 75 mg |  |  |
| Total subjects affected by serious adverse events    |                    |  |  |
| subjects affected / exposed                          | 4 / 22 (18.18%)    |  |  |
| number of deaths (all causes)                        | 0                  |  |  |
| number of deaths resulting from adverse events       | 0                  |  |  |
| Nervous system disorders                             |                    |  |  |
| Transient ischaemic attack                           |                    |  |  |
| subjects affected / exposed                          | 0 / 22 (0.00%)     |  |  |
| occurrences causally related to treatment / all      | 0 / 0              |  |  |
| deaths causally related to treatment / all           | 0 / 0              |  |  |
| General disorders and administration site conditions |                    |  |  |
| Death                                                |                    |  |  |
| subjects affected / exposed                          | 0 / 22 (0.00%)     |  |  |
| occurrences causally related to treatment / all      | 0 / 0              |  |  |
| deaths causally related to treatment / all           | 0 / 0              |  |  |
| Gastrointestinal disorders                           |                    |  |  |
| Abdominal pain upper                                 |                    |  |  |
| subjects affected / exposed                          | 0 / 22 (0.00%)     |  |  |
| occurrences causally related to treatment / all      | 0 / 0              |  |  |
| deaths causally related to treatment / all           | 0 / 0              |  |  |
| Colitis                                              |                    |  |  |
| subjects affected / exposed                          | 1 / 22 (4.55%)     |  |  |
| occurrences causally related to treatment / all      | 0 / 1              |  |  |
| deaths causally related to treatment / all           | 0 / 0              |  |  |
| Respiratory, thoracic and mediastinal disorders      |                    |  |  |
| Nasal septum deviation                               |                    |  |  |

|                                                 |                |  |  |
|-------------------------------------------------|----------------|--|--|
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Skin and subcutaneous tissue disorders          |                |  |  |
| Hidradenitis                                    |                |  |  |
| subjects affected / exposed                     | 1 / 22 (4.55%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Neurodermatitis                                 |                |  |  |
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Psychiatric disorders                           |                |  |  |
| Anxiety                                         |                |  |  |
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Musculoskeletal and connective tissue disorders |                |  |  |
| Intervertebral disc protrusion                  |                |  |  |
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Myopathy                                        |                |  |  |
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Infections and infestations                     |                |  |  |
| Appendicitis                                    |                |  |  |
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| COVID-19                                        |                |  |  |

|                                                 |                |  |  |
|-------------------------------------------------|----------------|--|--|
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Erysipelas                                      |                |  |  |
| subjects affected / exposed                     | 1 / 22 (4.55%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Mastitis                                        |                |  |  |
| subjects affected / exposed                     | 1 / 22 (4.55%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Pneumonia                                       |                |  |  |
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Tooth infection                                 |                |  |  |
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | Placebo        | Placebo to povorcitinib 75 mg | Povorcitinib 15 mg |
|-------------------------------------------------------|----------------|-------------------------------|--------------------|
| Total subjects affected by non-serious adverse events |                |                               |                    |
| subjects affected / exposed                           | 2 / 6 (33.33%) | 19 / 30 (63.33%)              | 4 / 7 (57.14%)     |
| Vascular disorders                                    |                |                               |                    |
| Hypertension                                          |                |                               |                    |
| subjects affected / exposed                           | 0 / 6 (0.00%)  | 1 / 30 (3.33%)                | 0 / 7 (0.00%)      |
| occurrences (all)                                     | 0              | 1                             | 0                  |
| General disorders and administration site conditions  |                |                               |                    |
| Asthenia                                              |                |                               |                    |
| subjects affected / exposed                           | 0 / 6 (0.00%)  | 0 / 30 (0.00%)                | 0 / 7 (0.00%)      |
| occurrences (all)                                     | 0              | 0                             | 0                  |
| Chest pain                                            |                |                               |                    |

|                                                                                                                     |                     |                      |                     |
|---------------------------------------------------------------------------------------------------------------------|---------------------|----------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                                                                    | 0 / 6 (0.00%)<br>0  | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Fatigue<br>subjects affected / exposed<br>occurrences (all)                                                         | 0 / 6 (0.00%)<br>0  | 3 / 30 (10.00%)<br>3 | 1 / 7 (14.29%)<br>1 |
| Mucosal dryness<br>subjects affected / exposed<br>occurrences (all)                                                 | 0 / 6 (0.00%)<br>0  | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Reproductive system and breast disorders<br>Ejaculation failure<br>subjects affected / exposed<br>occurrences (all) | 0 / 6 (0.00%)<br>0  | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Uterine polyp<br>subjects affected / exposed<br>occurrences (all)                                                   | 0 / 6 (0.00%)<br>0  | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Respiratory, thoracic and mediastinal disorders<br>Asthma<br>subjects affected / exposed<br>occurrences (all)       | 0 / 6 (0.00%)<br>0  | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Cough<br>subjects affected / exposed<br>occurrences (all)                                                           | 0 / 6 (0.00%)<br>0  | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Epistaxis<br>subjects affected / exposed<br>occurrences (all)                                                       | 0 / 6 (0.00%)<br>0  | 2 / 30 (6.67%)<br>2  | 0 / 7 (0.00%)<br>0  |
| Oropharyngeal pain<br>subjects affected / exposed<br>occurrences (all)                                              | 0 / 6 (0.00%)<br>0  | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Psychiatric disorders<br>Depression<br>subjects affected / exposed<br>occurrences (all)                             | 1 / 6 (16.67%)<br>1 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Investigations<br>Aspergillus test positive<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 6 (0.00%)<br>0  | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |

|                                                                                                                 |                    |                      |                     |
|-----------------------------------------------------------------------------------------------------------------|--------------------|----------------------|---------------------|
| Blood creatine phosphokinase increased<br>subjects affected / exposed<br>occurrences (all)                      | 0 / 6 (0.00%)<br>0 | 2 / 30 (6.67%)<br>2  | 0 / 7 (0.00%)<br>0  |
| Haemoglobin decreased<br>subjects affected / exposed<br>occurrences (all)                                       | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Platelet count decreased<br>subjects affected / exposed<br>occurrences (all)                                    | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Weight increased<br>subjects affected / exposed<br>occurrences (all)                                            | 0 / 6 (0.00%)<br>0 | 3 / 30 (10.00%)<br>3 | 0 / 7 (0.00%)<br>0  |
| Injury, poisoning and procedural complications<br>Contusion<br>subjects affected / exposed<br>occurrences (all) | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Joint capsule rupture<br>subjects affected / exposed<br>occurrences (all)                                       | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Muscle strain<br>subjects affected / exposed<br>occurrences (all)                                               | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Ligament sprain<br>subjects affected / exposed<br>occurrences (all)                                             | 0 / 6 (0.00%)<br>0 | 1 / 30 (3.33%)<br>1  | 1 / 7 (14.29%)<br>1 |
| Cardiac disorders<br>Sinus tachycardia<br>subjects affected / exposed<br>occurrences (all)                      | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Nervous system disorders<br>Dizziness<br>subjects affected / exposed<br>occurrences (all)                       | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Headache<br>subjects affected / exposed<br>occurrences (all)                                                    | 0 / 6 (0.00%)<br>0 | 1 / 30 (3.33%)<br>1  | 0 / 7 (0.00%)<br>0  |

|                                                                                                              |                    |                     |                     |
|--------------------------------------------------------------------------------------------------------------|--------------------|---------------------|---------------------|
| Intercostal neuralgia<br>subjects affected / exposed<br>occurrences (all)                                    | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Migraine<br>subjects affected / exposed<br>occurrences (all)                                                 | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Paraesthesia<br>subjects affected / exposed<br>occurrences (all)                                             | 0 / 6 (0.00%)<br>0 | 1 / 30 (3.33%)<br>1 | 1 / 7 (14.29%)<br>1 |
| Polyneuropathy<br>subjects affected / exposed<br>occurrences (all)                                           | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Presyncope<br>subjects affected / exposed<br>occurrences (all)                                               | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Blood and lymphatic system disorders<br>Thrombocytopenia<br>subjects affected / exposed<br>occurrences (all) | 0 / 6 (0.00%)<br>0 | 2 / 30 (6.67%)<br>2 | 0 / 7 (0.00%)<br>0  |
| Ear and labyrinth disorders<br>Ear discomfort<br>subjects affected / exposed<br>occurrences (all)            | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Vertigo<br>subjects affected / exposed<br>occurrences (all)                                                  | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Eye disorders<br>Blepharospasm<br>subjects affected / exposed<br>occurrences (all)                           | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Blepharitis<br>subjects affected / exposed<br>occurrences (all)                                              | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Eye pain<br>subjects affected / exposed<br>occurrences (all)                                                 | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0 | 0 / 7 (0.00%)<br>0  |
| Gastrointestinal disorders                                                                                   |                    |                     |                     |

|                                        |               |                |                |
|----------------------------------------|---------------|----------------|----------------|
| Diarrhoea                              |               |                |                |
| subjects affected / exposed            | 0 / 6 (0.00%) | 2 / 30 (6.67%) | 0 / 7 (0.00%)  |
| occurrences (all)                      | 0             | 2              | 0              |
| Constipation                           |               |                |                |
| subjects affected / exposed            | 0 / 6 (0.00%) | 1 / 30 (3.33%) | 0 / 7 (0.00%)  |
| occurrences (all)                      | 0             | 1              | 0              |
| Dry mouth                              |               |                |                |
| subjects affected / exposed            | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%)  |
| occurrences (all)                      | 0             | 0              | 0              |
| Dyspepsia                              |               |                |                |
| subjects affected / exposed            | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%)  |
| occurrences (all)                      | 0             | 0              | 0              |
| Dysphagia                              |               |                |                |
| subjects affected / exposed            | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%)  |
| occurrences (all)                      | 0             | 0              | 0              |
| Loose tooth                            |               |                |                |
| subjects affected / exposed            | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%)  |
| occurrences (all)                      | 0             | 0              | 0              |
| Nausea                                 |               |                |                |
| subjects affected / exposed            | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all)                      | 0             | 0              | 1              |
| Trichoglossia                          |               |                |                |
| subjects affected / exposed            | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%)  |
| occurrences (all)                      | 0             | 0              | 0              |
| Skin and subcutaneous tissue disorders |               |                |                |
| Alopecia                               |               |                |                |
| subjects affected / exposed            | 0 / 6 (0.00%) | 1 / 30 (3.33%) | 0 / 7 (0.00%)  |
| occurrences (all)                      | 0             | 1              | 0              |
| Dermatitis contact                     |               |                |                |
| subjects affected / exposed            | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%)  |
| occurrences (all)                      | 0             | 0              | 0              |
| Diffuse alopecia                       |               |                |                |
| subjects affected / exposed            | 0 / 6 (0.00%) | 0 / 30 (0.00%) | 0 / 7 (0.00%)  |
| occurrences (all)                      | 0             | 0              | 0              |
| Dry skin                               |               |                |                |

|                             |               |                 |               |
|-----------------------------|---------------|-----------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 30 (0.00%)  | 0 / 7 (0.00%) |
| occurrences (all)           | 0             | 0               | 0             |
| Erythema                    |               |                 |               |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 30 (0.00%)  | 0 / 7 (0.00%) |
| occurrences (all)           | 0             | 0               | 0             |
| Hyperhidrosis               |               |                 |               |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 30 (0.00%)  | 0 / 7 (0.00%) |
| occurrences (all)           | 0             | 0               | 0             |
| Lichen myxoedematosus       |               |                 |               |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 30 (0.00%)  | 0 / 7 (0.00%) |
| occurrences (all)           | 0             | 0               | 0             |
| Neurodermatitis             |               |                 |               |
| subjects affected / exposed | 0 / 6 (0.00%) | 4 / 30 (13.33%) | 0 / 7 (0.00%) |
| occurrences (all)           | 0             | 4               | 0             |
| Perioral dermatitis         |               |                 |               |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 30 (0.00%)  | 0 / 7 (0.00%) |
| occurrences (all)           | 0             | 0               | 0             |
| Rosacea                     |               |                 |               |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 30 (0.00%)  | 0 / 7 (0.00%) |
| occurrences (all)           | 0             | 0               | 0             |
| Seborrhoeic dermatitis      |               |                 |               |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 30 (0.00%)  | 0 / 7 (0.00%) |
| occurrences (all)           | 0             | 0               | 0             |
| Skin mass                   |               |                 |               |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 30 (0.00%)  | 0 / 7 (0.00%) |
| occurrences (all)           | 0             | 0               | 0             |
| Trichorrhexis               |               |                 |               |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 30 (0.00%)  | 0 / 7 (0.00%) |
| occurrences (all)           | 0             | 0               | 0             |
| Renal and urinary disorders |               |                 |               |
| Dysuria                     |               |                 |               |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 30 (0.00%)  | 0 / 7 (0.00%) |
| occurrences (all)           | 0             | 0               | 0             |
| Pollakiuria                 |               |                 |               |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 30 (0.00%)  | 0 / 7 (0.00%) |
| occurrences (all)           | 0             | 0               | 0             |

|                                                                              |                    |                      |                     |
|------------------------------------------------------------------------------|--------------------|----------------------|---------------------|
| Urinary incontinence<br>subjects affected / exposed<br>occurrences (all)     | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Musculoskeletal and connective tissue disorders                              |                    |                      |                     |
| Back pain<br>subjects affected / exposed<br>occurrences (all)                | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Myalgia<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Pain in extremity<br>subjects affected / exposed<br>occurrences (all)        | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Pain in jaw<br>subjects affected / exposed<br>occurrences (all)              | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Spinal pain<br>subjects affected / exposed<br>occurrences (all)              | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Infections and infestations                                                  |                    |                      |                     |
| Asymptomatic bacteriuria<br>subjects affected / exposed<br>occurrences (all) | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Cellulitis<br>subjects affected / exposed<br>occurrences (all)               | 0 / 6 (0.00%)<br>0 | 1 / 30 (3.33%)<br>1  | 0 / 7 (0.00%)<br>0  |
| COVID-19<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 6 (0.00%)<br>0 | 3 / 30 (10.00%)<br>3 | 1 / 7 (14.29%)<br>1 |
| Bronchitis<br>subjects affected / exposed<br>occurrences (all)               | 0 / 6 (0.00%)<br>0 | 2 / 30 (6.67%)<br>3  | 0 / 7 (0.00%)<br>0  |
| Cystitis<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 6 (0.00%)<br>0 | 0 / 30 (0.00%)<br>0  | 0 / 7 (0.00%)<br>0  |
| Eyelid folliculitis                                                          |                    |                      |                     |

|                             |                |                 |                |
|-----------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 6 (0.00%)  | 0 / 30 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 0               | 0              |
| Folliculitis                |                |                 |                |
| subjects affected / exposed | 0 / 6 (0.00%)  | 0 / 30 (0.00%)  | 1 / 7 (14.29%) |
| occurrences (all)           | 0              | 0               | 1              |
| Gastroenteritis             |                |                 |                |
| subjects affected / exposed | 0 / 6 (0.00%)  | 3 / 30 (10.00%) | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 3               | 0              |
| Gastrointestinal infection  |                |                 |                |
| subjects affected / exposed | 0 / 6 (0.00%)  | 0 / 30 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 0               | 0              |
| Herpes zoster               |                |                 |                |
| subjects affected / exposed | 1 / 6 (16.67%) | 0 / 30 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 1              | 0               | 0              |
| Herpes simplex              |                |                 |                |
| subjects affected / exposed | 0 / 6 (0.00%)  | 0 / 30 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 0               | 0              |
| Influenza                   |                |                 |                |
| subjects affected / exposed | 0 / 6 (0.00%)  | 0 / 30 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 0               | 0              |
| Nasopharyngitis             |                |                 |                |
| subjects affected / exposed | 0 / 6 (0.00%)  | 5 / 30 (16.67%) | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 7               | 0              |
| Otitis externa              |                |                 |                |
| subjects affected / exposed | 0 / 6 (0.00%)  | 0 / 30 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 0               | 0              |
| Oral herpes                 |                |                 |                |
| subjects affected / exposed | 0 / 6 (0.00%)  | 1 / 30 (3.33%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 1               | 0              |
| Oral candidiasis            |                |                 |                |
| subjects affected / exposed | 0 / 6 (0.00%)  | 1 / 30 (3.33%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 1               | 0              |
| Pneumonia                   |                |                 |                |
| subjects affected / exposed | 0 / 6 (0.00%)  | 0 / 30 (0.00%)  | 0 / 7 (0.00%)  |
| occurrences (all)           | 0              | 0               | 0              |
| Pulpitis dental             |                |                 |                |

|                                    |                |                |                |
|------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed        | 0 / 6 (0.00%)  | 0 / 30 (0.00%) | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 0              | 0              |
| Sinusitis                          |                |                |                |
| subjects affected / exposed        | 1 / 6 (16.67%) | 0 / 30 (0.00%) | 0 / 7 (0.00%)  |
| occurrences (all)                  | 1              | 0              | 0              |
| Skin candida                       |                |                |                |
| subjects affected / exposed        | 0 / 6 (0.00%)  | 0 / 30 (0.00%) | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 0              | 0              |
| Skin infection                     |                |                |                |
| subjects affected / exposed        | 0 / 6 (0.00%)  | 0 / 30 (0.00%) | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 0              | 0              |
| Tooth infection                    |                |                |                |
| subjects affected / exposed        | 0 / 6 (0.00%)  | 2 / 30 (6.67%) | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 2              | 0              |
| Tonsillitis                        |                |                |                |
| subjects affected / exposed        | 0 / 6 (0.00%)  | 0 / 30 (0.00%) | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 0              | 0              |
| Upper respiratory tract infection  |                |                |                |
| subjects affected / exposed        | 0 / 6 (0.00%)  | 1 / 30 (3.33%) | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 1              | 0              |
| Vulvovaginal mycotic infection     |                |                |                |
| subjects affected / exposed        | 0 / 6 (0.00%)  | 0 / 30 (0.00%) | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 0              | 0              |
| Urinary tract infection            |                |                |                |
| subjects affected / exposed        | 0 / 6 (0.00%)  | 2 / 30 (6.67%) | 1 / 7 (14.29%) |
| occurrences (all)                  | 0              | 2              | 1              |
| Metabolism and nutrition disorders |                |                |                |
| Hypercholesterolaemia              |                |                |                |
| subjects affected / exposed        | 0 / 6 (0.00%)  | 0 / 30 (0.00%) | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 0              | 0              |
| Hyperkalaemia                      |                |                |                |
| subjects affected / exposed        | 0 / 6 (0.00%)  | 0 / 30 (0.00%) | 0 / 7 (0.00%)  |
| occurrences (all)                  | 0              | 0              | 0              |
| Increased appetite                 |                |                |                |
| subjects affected / exposed        | 0 / 6 (0.00%)  | 0 / 30 (0.00%) | 1 / 7 (14.29%) |
| occurrences (all)                  | 0              | 0              | 1              |

| <b>Non-serious adverse events</b>                                                                                                                                                                                                                                                                                                        | Placebo to povorcitinib 45 mg                                                                    | Povorcitinib 15 mg to 45 mg                                                                       | Povorcitinib 45 mg to 75 mg                                                                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed                                                                                                                                                                                                                                                     | 0 / 1 (0.00%)                                                                                    | 3 / 4 (75.00%)                                                                                    | 20 / 23 (86.96%)                                                                                      |
| Vascular disorders<br>Hypertension<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                                   | 0 / 1 (0.00%)<br>0                                                                               | 1 / 4 (25.00%)<br>1                                                                               | 2 / 23 (8.70%)<br>2                                                                                   |
| General disorders and administration site conditions<br>Asthenia<br>subjects affected / exposed<br>occurrences (all)<br><br>Chest pain<br>subjects affected / exposed<br>occurrences (all)<br><br>Fatigue<br>subjects affected / exposed<br>occurrences (all)<br><br>Mucosal dryness<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0<br><br>0 / 1 (0.00%)<br>0<br><br>0 / 1 (0.00%)<br>0<br><br>0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0<br><br>0 / 4 (0.00%)<br>0<br><br>2 / 4 (50.00%)<br>2<br><br>0 / 4 (0.00%)<br>0 | 0 / 23 (0.00%)<br>0<br><br>1 / 23 (4.35%)<br>1<br><br>3 / 23 (13.04%)<br>3<br><br>0 / 23 (0.00%)<br>0 |
| Reproductive system and breast disorders<br>Ejaculation failure<br>subjects affected / exposed<br>occurrences (all)<br><br>Uterine polyp<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                             | 0 / 1 (0.00%)<br>0<br><br>0 / 1 (0.00%)<br>0                                                     | 0 / 4 (0.00%)<br>0<br><br>1 / 4 (25.00%)<br>1                                                     | 0 / 23 (0.00%)<br>0<br><br>0 / 23 (0.00%)<br>0                                                        |
| Respiratory, thoracic and mediastinal disorders<br>Asthma<br>subjects affected / exposed<br>occurrences (all)<br><br>Cough<br>subjects affected / exposed<br>occurrences (all)<br><br>Epistaxis                                                                                                                                          | 0 / 1 (0.00%)<br>0<br><br>0 / 1 (0.00%)<br>0                                                     | 0 / 4 (0.00%)<br>0<br><br>0 / 4 (0.00%)<br>0                                                      | 1 / 23 (4.35%)<br>1<br><br>2 / 23 (8.70%)<br>2                                                        |

|                                                |               |                |                 |
|------------------------------------------------|---------------|----------------|-----------------|
| subjects affected / exposed                    | 0 / 1 (0.00%) | 1 / 4 (25.00%) | 0 / 23 (0.00%)  |
| occurrences (all)                              | 0             | 1              | 0               |
| Oropharyngeal pain                             |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%)  |
| occurrences (all)                              | 0             | 0              | 0               |
| Psychiatric disorders                          |               |                |                 |
| Depression                                     |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 1 / 23 (4.35%)  |
| occurrences (all)                              | 0             | 0              | 1               |
| Investigations                                 |               |                |                 |
| Aspergillus test positive                      |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%)  |
| occurrences (all)                              | 0             | 0              | 0               |
| Blood creatine phosphokinase increased         |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 4 / 23 (17.39%) |
| occurrences (all)                              | 0             | 0              | 4               |
| Haemoglobin decreased                          |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 3 / 23 (13.04%) |
| occurrences (all)                              | 0             | 0              | 3               |
| Platelet count decreased                       |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%)  |
| occurrences (all)                              | 0             | 0              | 0               |
| Weight increased                               |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 1 / 4 (25.00%) | 2 / 23 (8.70%)  |
| occurrences (all)                              | 0             | 1              | 2               |
| Injury, poisoning and procedural complications |               |                |                 |
| Contusion                                      |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 1 / 4 (25.00%) | 2 / 23 (8.70%)  |
| occurrences (all)                              | 0             | 1              | 2               |
| Joint capsule rupture                          |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%)  |
| occurrences (all)                              | 0             | 0              | 0               |
| Muscle strain                                  |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%)  |
| occurrences (all)                              | 0             | 0              | 0               |
| Ligament sprain                                |               |                |                 |

|                                                                                                              |                    |                     |                      |
|--------------------------------------------------------------------------------------------------------------|--------------------|---------------------|----------------------|
| subjects affected / exposed<br>occurrences (all)                                                             | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0  | 0 / 23 (0.00%)<br>0  |
| Cardiac disorders<br>Sinus tachycardia<br>subjects affected / exposed<br>occurrences (all)                   | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0  | 0 / 23 (0.00%)<br>0  |
| Nervous system disorders<br>Dizziness<br>subjects affected / exposed<br>occurrences (all)                    | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0  | 1 / 23 (4.35%)<br>1  |
| Headache<br>subjects affected / exposed<br>occurrences (all)                                                 | 0 / 1 (0.00%)<br>0 | 1 / 4 (25.00%)<br>2 | 4 / 23 (17.39%)<br>7 |
| Intercostal neuralgia<br>subjects affected / exposed<br>occurrences (all)                                    | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0  | 0 / 23 (0.00%)<br>0  |
| Migraine<br>subjects affected / exposed<br>occurrences (all)                                                 | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0  | 0 / 23 (0.00%)<br>0  |
| Paraesthesia<br>subjects affected / exposed<br>occurrences (all)                                             | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0  | 0 / 23 (0.00%)<br>0  |
| Polyneuropathy<br>subjects affected / exposed<br>occurrences (all)                                           | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0  | 0 / 23 (0.00%)<br>0  |
| Presyncope<br>subjects affected / exposed<br>occurrences (all)                                               | 0 / 1 (0.00%)<br>0 | 1 / 4 (25.00%)<br>1 | 0 / 23 (0.00%)<br>0  |
| Blood and lymphatic system disorders<br>Thrombocytopenia<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0  | 0 / 23 (0.00%)<br>0  |
| Ear and labyrinth disorders<br>Ear discomfort<br>subjects affected / exposed<br>occurrences (all)            | 0 / 1 (0.00%)<br>0 | 1 / 4 (25.00%)<br>1 | 0 / 23 (0.00%)<br>0  |
| Vertigo                                                                                                      |                    |                     |                      |

|                                                  |                    |                    |                     |
|--------------------------------------------------|--------------------|--------------------|---------------------|
| subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 | 0 / 23 (0.00%)<br>0 |
| Eye disorders                                    |                    |                    |                     |
| Blepharospasm                                    |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 0 / 23 (0.00%)      |
| occurrences (all)                                | 0                  | 0                  | 0                   |
| Blepharitis                                      |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 0 / 23 (0.00%)      |
| occurrences (all)                                | 0                  | 0                  | 0                   |
| Eye pain                                         |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 0 / 23 (0.00%)      |
| occurrences (all)                                | 0                  | 0                  | 0                   |
| Gastrointestinal disorders                       |                    |                    |                     |
| Diarrhoea                                        |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 0 / 23 (0.00%)      |
| occurrences (all)                                | 0                  | 0                  | 0                   |
| Constipation                                     |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 2 / 23 (8.70%)      |
| occurrences (all)                                | 0                  | 0                  | 2                   |
| Dry mouth                                        |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 2 / 23 (8.70%)      |
| occurrences (all)                                | 0                  | 0                  | 2                   |
| Dyspepsia                                        |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 0 / 23 (0.00%)      |
| occurrences (all)                                | 0                  | 0                  | 0                   |
| Dysphagia                                        |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 0 / 23 (0.00%)      |
| occurrences (all)                                | 0                  | 0                  | 0                   |
| Loose tooth                                      |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 0 / 23 (0.00%)      |
| occurrences (all)                                | 0                  | 0                  | 0                   |
| Nausea                                           |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 1 / 23 (4.35%)      |
| occurrences (all)                                | 0                  | 0                  | 1                   |
| Trichoglossia                                    |                    |                    |                     |

|                                                  |                    |                    |                     |
|--------------------------------------------------|--------------------|--------------------|---------------------|
| subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 | 0 / 23 (0.00%)<br>0 |
| Skin and subcutaneous tissue disorders           |                    |                    |                     |
| Alopecia                                         |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 1 / 4 (25.00%)     | 0 / 23 (0.00%)      |
| occurrences (all)                                | 0                  | 1                  | 0                   |
| Dermatitis contact                               |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 2 / 23 (8.70%)      |
| occurrences (all)                                | 0                  | 0                  | 2                   |
| Diffuse alopecia                                 |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 0 / 23 (0.00%)      |
| occurrences (all)                                | 0                  | 0                  | 0                   |
| Dry skin                                         |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 1 / 4 (25.00%)     | 0 / 23 (0.00%)      |
| occurrences (all)                                | 0                  | 1                  | 0                   |
| Erythema                                         |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 0 / 23 (0.00%)      |
| occurrences (all)                                | 0                  | 0                  | 0                   |
| Hyperhidrosis                                    |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 0 / 23 (0.00%)      |
| occurrences (all)                                | 0                  | 0                  | 0                   |
| Lichen myxoedematosus                            |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 0 / 23 (0.00%)      |
| occurrences (all)                                | 0                  | 0                  | 0                   |
| Neurodermatitis                                  |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 1 / 23 (4.35%)      |
| occurrences (all)                                | 0                  | 0                  | 1                   |
| Perioral dermatitis                              |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 0 / 23 (0.00%)      |
| occurrences (all)                                | 0                  | 0                  | 0                   |
| Rosacea                                          |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 0 / 23 (0.00%)      |
| occurrences (all)                                | 0                  | 0                  | 0                   |
| Seborrhoeic dermatitis                           |                    |                    |                     |
| subjects affected / exposed                      | 0 / 1 (0.00%)      | 0 / 4 (0.00%)      | 1 / 23 (4.35%)      |
| occurrences (all)                                | 0                  | 0                  | 1                   |

|                                                                                                                  |                    |                     |                      |
|------------------------------------------------------------------------------------------------------------------|--------------------|---------------------|----------------------|
| Skin mass<br>subjects affected / exposed<br>occurrences (all)                                                    | 0 / 1 (0.00%)<br>0 | 1 / 4 (25.00%)<br>1 | 0 / 23 (0.00%)<br>0  |
| Trichorrhexis<br>subjects affected / exposed<br>occurrences (all)                                                | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0  | 0 / 23 (0.00%)<br>0  |
| Renal and urinary disorders<br>Dysuria<br>subjects affected / exposed<br>occurrences (all)                       | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0  | 1 / 23 (4.35%)<br>1  |
| Pollakiuria<br>subjects affected / exposed<br>occurrences (all)                                                  | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0  | 0 / 23 (0.00%)<br>0  |
| Urinary incontinence<br>subjects affected / exposed<br>occurrences (all)                                         | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0  | 0 / 23 (0.00%)<br>0  |
| Musculoskeletal and connective tissue disorders<br>Back pain<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0  | 4 / 23 (17.39%)<br>4 |
| Myalgia<br>subjects affected / exposed<br>occurrences (all)                                                      | 0 / 1 (0.00%)<br>0 | 1 / 4 (25.00%)<br>1 | 0 / 23 (0.00%)<br>0  |
| Pain in extremity<br>subjects affected / exposed<br>occurrences (all)                                            | 0 / 1 (0.00%)<br>0 | 1 / 4 (25.00%)<br>1 | 1 / 23 (4.35%)<br>1  |
| Pain in jaw<br>subjects affected / exposed<br>occurrences (all)                                                  | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0  | 0 / 23 (0.00%)<br>0  |
| Spinal pain<br>subjects affected / exposed<br>occurrences (all)                                                  | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0  | 0 / 23 (0.00%)<br>0  |
| Infections and infestations<br>Asymptomatic bacteriuria<br>subjects affected / exposed<br>occurrences (all)      | 0 / 1 (0.00%)<br>0 | 1 / 4 (25.00%)<br>1 | 0 / 23 (0.00%)<br>0  |

|                             |               |                |                 |
|-----------------------------|---------------|----------------|-----------------|
| Cellulitis                  |               |                |                 |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%)  |
| occurrences (all)           | 0             | 0              | 0               |
| COVID-19                    |               |                |                 |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 2 / 23 (8.70%)  |
| occurrences (all)           | 0             | 0              | 2               |
| Bronchitis                  |               |                |                 |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 1 / 23 (4.35%)  |
| occurrences (all)           | 0             | 0              | 1               |
| Cystitis                    |               |                |                 |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%)  |
| occurrences (all)           | 0             | 0              | 0               |
| Eyelid folliculitis         |               |                |                 |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%)  |
| occurrences (all)           | 0             | 0              | 0               |
| Folliculitis                |               |                |                 |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 3 / 23 (13.04%) |
| occurrences (all)           | 0             | 0              | 3               |
| Gastroenteritis             |               |                |                 |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 1 / 23 (4.35%)  |
| occurrences (all)           | 0             | 0              | 1               |
| Gastrointestinal infection  |               |                |                 |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 1 / 23 (4.35%)  |
| occurrences (all)           | 0             | 0              | 1               |
| Herpes zoster               |               |                |                 |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%)  |
| occurrences (all)           | 0             | 0              | 0               |
| Herpes simplex              |               |                |                 |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%)  |
| occurrences (all)           | 0             | 0              | 0               |
| Influenza                   |               |                |                 |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%)  |
| occurrences (all)           | 0             | 0              | 0               |
| Nasopharyngitis             |               |                |                 |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 4 (25.00%) | 2 / 23 (8.70%)  |
| occurrences (all)           | 0             | 1              | 4               |

|                                   |               |                |                |
|-----------------------------------|---------------|----------------|----------------|
| Otitis externa                    |               |                |                |
| subjects affected / exposed       | 0 / 1 (0.00%) | 1 / 4 (25.00%) | 0 / 23 (0.00%) |
| occurrences (all)                 | 0             | 1              | 0              |
| Oral herpes                       |               |                |                |
| subjects affected / exposed       | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%) |
| occurrences (all)                 | 0             | 0              | 0              |
| Oral candidiasis                  |               |                |                |
| subjects affected / exposed       | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 1 / 23 (4.35%) |
| occurrences (all)                 | 0             | 0              | 1              |
| Pneumonia                         |               |                |                |
| subjects affected / exposed       | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%) |
| occurrences (all)                 | 0             | 0              | 0              |
| Pulpitis dental                   |               |                |                |
| subjects affected / exposed       | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%) |
| occurrences (all)                 | 0             | 0              | 0              |
| Sinusitis                         |               |                |                |
| subjects affected / exposed       | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%) |
| occurrences (all)                 | 0             | 0              | 0              |
| Skin candida                      |               |                |                |
| subjects affected / exposed       | 0 / 1 (0.00%) | 1 / 4 (25.00%) | 0 / 23 (0.00%) |
| occurrences (all)                 | 0             | 1              | 0              |
| Skin infection                    |               |                |                |
| subjects affected / exposed       | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%) |
| occurrences (all)                 | 0             | 0              | 0              |
| Tooth infection                   |               |                |                |
| subjects affected / exposed       | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%) |
| occurrences (all)                 | 0             | 0              | 0              |
| Tonsillitis                       |               |                |                |
| subjects affected / exposed       | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%) |
| occurrences (all)                 | 0             | 0              | 0              |
| Upper respiratory tract infection |               |                |                |
| subjects affected / exposed       | 0 / 1 (0.00%) | 1 / 4 (25.00%) | 1 / 23 (4.35%) |
| occurrences (all)                 | 0             | 2              | 1              |
| Vulvovaginal mycotic infection    |               |                |                |
| subjects affected / exposed       | 0 / 1 (0.00%) | 0 / 4 (0.00%)  | 0 / 23 (0.00%) |
| occurrences (all)                 | 0             | 0              | 0              |

|                                                                             |                    |                    |                     |
|-----------------------------------------------------------------------------|--------------------|--------------------|---------------------|
| Urinary tract infection<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 | 0 / 23 (0.00%)<br>0 |
| Metabolism and nutrition disorders                                          |                    |                    |                     |
| Hypercholesterolaemia<br>subjects affected / exposed<br>occurrences (all)   | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 | 0 / 23 (0.00%)<br>0 |
| Hyperkalaemia<br>subjects affected / exposed<br>occurrences (all)           | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 | 0 / 23 (0.00%)<br>0 |
| Increased appetite<br>subjects affected / exposed<br>occurrences (all)      | 0 / 1 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 | 0 / 23 (0.00%)<br>0 |

| <b>Non-serious adverse events</b>                                                       | Povorcitinib 15 mg<br>to 75 mg | Povorcitinib 45 mg  | Povorcitinib 75 mg<br>to 45 mg |
|-----------------------------------------------------------------------------------------|--------------------------------|---------------------|--------------------------------|
| Total subjects affected by non-serious<br>adverse events<br>subjects affected / exposed | 19 / 25 (76.00%)               | 7 / 12 (58.33%)     | 12 / 15 (80.00%)               |
| Vascular disorders                                                                      |                                |                     |                                |
| Hypertension<br>subjects affected / exposed<br>occurrences (all)                        | 1 / 25 (4.00%)<br>1            | 0 / 12 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0            |
| General disorders and administration<br>site conditions                                 |                                |                     |                                |
| Asthenia<br>subjects affected / exposed<br>occurrences (all)                            | 0 / 25 (0.00%)<br>0            | 0 / 12 (0.00%)<br>0 | 1 / 15 (6.67%)<br>1            |
| Chest pain<br>subjects affected / exposed<br>occurrences (all)                          | 0 / 25 (0.00%)<br>0            | 1 / 12 (8.33%)<br>1 | 0 / 15 (0.00%)<br>0            |
| Fatigue<br>subjects affected / exposed<br>occurrences (all)                             | 4 / 25 (16.00%)<br>6           | 0 / 12 (0.00%)<br>0 | 2 / 15 (13.33%)<br>2           |
| Mucosal dryness<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 25 (0.00%)<br>0            | 0 / 12 (0.00%)<br>0 | 1 / 15 (6.67%)<br>1            |
| Reproductive system and breast<br>disorders                                             |                                |                     |                                |

|                                                                                            |                      |                     |                      |
|--------------------------------------------------------------------------------------------|----------------------|---------------------|----------------------|
| Ejaculation failure<br>subjects affected / exposed<br>occurrences (all)                    | 0 / 25 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0 | 1 / 15 (6.67%)<br>1  |
| Uterine polyp<br>subjects affected / exposed<br>occurrences (all)                          | 0 / 25 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0  |
| Respiratory, thoracic and mediastinal disorders                                            |                      |                     |                      |
| Asthma<br>subjects affected / exposed<br>occurrences (all)                                 | 0 / 25 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0  |
| Cough<br>subjects affected / exposed<br>occurrences (all)                                  | 1 / 25 (4.00%)<br>1  | 0 / 12 (0.00%)<br>0 | 1 / 15 (6.67%)<br>1  |
| Epistaxis<br>subjects affected / exposed<br>occurrences (all)                              | 0 / 25 (0.00%)<br>0  | 1 / 12 (8.33%)<br>1 | 0 / 15 (0.00%)<br>0  |
| Oropharyngeal pain<br>subjects affected / exposed<br>occurrences (all)                     | 2 / 25 (8.00%)<br>2  | 1 / 12 (8.33%)<br>1 | 0 / 15 (0.00%)<br>0  |
| Psychiatric disorders                                                                      |                      |                     |                      |
| Depression<br>subjects affected / exposed<br>occurrences (all)                             | 0 / 25 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0  |
| Investigations                                                                             |                      |                     |                      |
| Aspergillus test positive<br>subjects affected / exposed<br>occurrences (all)              | 0 / 25 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0 | 1 / 15 (6.67%)<br>1  |
| Blood creatine phosphokinase increased<br>subjects affected / exposed<br>occurrences (all) | 1 / 25 (4.00%)<br>1  | 1 / 12 (8.33%)<br>2 | 1 / 15 (6.67%)<br>1  |
| Haemoglobin decreased<br>subjects affected / exposed<br>occurrences (all)                  | 5 / 25 (20.00%)<br>6 | 0 / 12 (0.00%)<br>0 | 3 / 15 (20.00%)<br>3 |
| Platelet count decreased<br>subjects affected / exposed<br>occurrences (all)               | 0 / 25 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0 | 1 / 15 (6.67%)<br>2  |

|                                                                           |                      |                      |                     |
|---------------------------------------------------------------------------|----------------------|----------------------|---------------------|
| Weight increased<br>subjects affected / exposed<br>occurrences (all)      | 0 / 25 (0.00%)<br>0  | 1 / 12 (8.33%)<br>1  | 0 / 15 (0.00%)<br>0 |
| Injury, poisoning and procedural complications                            |                      |                      |                     |
| Contusion<br>subjects affected / exposed<br>occurrences (all)             | 0 / 25 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0  | 0 / 15 (0.00%)<br>0 |
| Joint capsule rupture<br>subjects affected / exposed<br>occurrences (all) | 0 / 25 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1 |
| Muscle strain<br>subjects affected / exposed<br>occurrences (all)         | 0 / 25 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1 |
| Ligament sprain<br>subjects affected / exposed<br>occurrences (all)       | 0 / 25 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0  | 0 / 15 (0.00%)<br>0 |
| Cardiac disorders                                                         |                      |                      |                     |
| Sinus tachycardia<br>subjects affected / exposed<br>occurrences (all)     | 0 / 25 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1 |
| Nervous system disorders                                                  |                      |                      |                     |
| Dizziness<br>subjects affected / exposed<br>occurrences (all)             | 0 / 25 (0.00%)<br>0  | 1 / 12 (8.33%)<br>1  | 1 / 15 (6.67%)<br>1 |
| Headache<br>subjects affected / exposed<br>occurrences (all)              | 6 / 25 (24.00%)<br>6 | 2 / 12 (16.67%)<br>2 | 0 / 15 (0.00%)<br>0 |
| Intercostal neuralgia<br>subjects affected / exposed<br>occurrences (all) | 0 / 25 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0  | 1 / 15 (6.67%)<br>1 |
| Migraine<br>subjects affected / exposed<br>occurrences (all)              | 0 / 25 (0.00%)<br>0  | 1 / 12 (8.33%)<br>2  | 0 / 15 (0.00%)<br>0 |
| Paraesthesia<br>subjects affected / exposed<br>occurrences (all)          | 0 / 25 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0  | 0 / 15 (0.00%)<br>0 |

|                                                                                                              |                     |                     |                      |
|--------------------------------------------------------------------------------------------------------------|---------------------|---------------------|----------------------|
| Polyneuropathy<br>subjects affected / exposed<br>occurrences (all)                                           | 0 / 25 (0.00%)<br>0 | 1 / 12 (8.33%)<br>1 | 0 / 15 (0.00%)<br>0  |
| Presyncope<br>subjects affected / exposed<br>occurrences (all)                                               | 0 / 25 (0.00%)<br>0 | 0 / 12 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0  |
| Blood and lymphatic system disorders<br>Thrombocytopenia<br>subjects affected / exposed<br>occurrences (all) | 0 / 25 (0.00%)<br>0 | 0 / 12 (0.00%)<br>0 | 1 / 15 (6.67%)<br>1  |
| Ear and labyrinth disorders<br>Ear discomfort<br>subjects affected / exposed<br>occurrences (all)            | 0 / 25 (0.00%)<br>0 | 0 / 12 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0  |
| Vertigo<br>subjects affected / exposed<br>occurrences (all)                                                  | 0 / 25 (0.00%)<br>0 | 0 / 12 (0.00%)<br>0 | 1 / 15 (6.67%)<br>1  |
| Eye disorders<br>Blepharospasm<br>subjects affected / exposed<br>occurrences (all)                           | 0 / 25 (0.00%)<br>0 | 1 / 12 (8.33%)<br>1 | 0 / 15 (0.00%)<br>0  |
| Blepharitis<br>subjects affected / exposed<br>occurrences (all)                                              | 0 / 25 (0.00%)<br>0 | 1 / 12 (8.33%)<br>1 | 0 / 15 (0.00%)<br>0  |
| Eye pain<br>subjects affected / exposed<br>occurrences (all)                                                 | 0 / 25 (0.00%)<br>0 | 1 / 12 (8.33%)<br>1 | 0 / 15 (0.00%)<br>0  |
| Gastrointestinal disorders<br>Diarrhoea<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 25 (0.00%)<br>0 | 0 / 12 (0.00%)<br>0 | 2 / 15 (13.33%)<br>2 |
| Constipation<br>subjects affected / exposed<br>occurrences (all)                                             | 0 / 25 (0.00%)<br>0 | 0 / 12 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0  |
| Dry mouth<br>subjects affected / exposed<br>occurrences (all)                                                | 1 / 25 (4.00%)<br>2 | 1 / 12 (8.33%)<br>1 | 0 / 15 (0.00%)<br>0  |

|                                        |                 |                |                |
|----------------------------------------|-----------------|----------------|----------------|
| Dyspepsia                              |                 |                |                |
| subjects affected / exposed            | 0 / 25 (0.00%)  | 1 / 12 (8.33%) | 0 / 15 (0.00%) |
| occurrences (all)                      | 0               | 1              | 0              |
| Dysphagia                              |                 |                |                |
| subjects affected / exposed            | 0 / 25 (0.00%)  | 0 / 12 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all)                      | 0               | 0              | 1              |
| Loose tooth                            |                 |                |                |
| subjects affected / exposed            | 0 / 25 (0.00%)  | 1 / 12 (8.33%) | 0 / 15 (0.00%) |
| occurrences (all)                      | 0               | 1              | 0              |
| Nausea                                 |                 |                |                |
| subjects affected / exposed            | 3 / 25 (12.00%) | 1 / 12 (8.33%) | 0 / 15 (0.00%) |
| occurrences (all)                      | 4               | 1              | 0              |
| Trichoglossia                          |                 |                |                |
| subjects affected / exposed            | 0 / 25 (0.00%)  | 1 / 12 (8.33%) | 0 / 15 (0.00%) |
| occurrences (all)                      | 0               | 1              | 0              |
| Skin and subcutaneous tissue disorders |                 |                |                |
| Alopecia                               |                 |                |                |
| subjects affected / exposed            | 0 / 25 (0.00%)  | 0 / 12 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all)                      | 0               | 0              | 0              |
| Dermatitis contact                     |                 |                |                |
| subjects affected / exposed            | 0 / 25 (0.00%)  | 0 / 12 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all)                      | 0               | 0              | 0              |
| Diffuse alopecia                       |                 |                |                |
| subjects affected / exposed            | 0 / 25 (0.00%)  | 1 / 12 (8.33%) | 0 / 15 (0.00%) |
| occurrences (all)                      | 0               | 1              | 0              |
| Dry skin                               |                 |                |                |
| subjects affected / exposed            | 0 / 25 (0.00%)  | 0 / 12 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all)                      | 0               | 0              | 0              |
| Erythema                               |                 |                |                |
| subjects affected / exposed            | 0 / 25 (0.00%)  | 0 / 12 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all)                      | 0               | 0              | 1              |
| Hyperhidrosis                          |                 |                |                |
| subjects affected / exposed            | 0 / 25 (0.00%)  | 1 / 12 (8.33%) | 0 / 15 (0.00%) |
| occurrences (all)                      | 0               | 1              | 0              |
| Lichen myxoedematosus                  |                 |                |                |

|                                                 |                 |                |                |
|-------------------------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 25 (0.00%)  | 0 / 12 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all)                               | 0               | 0              | 1              |
| Neurodermatitis                                 |                 |                |                |
| subjects affected / exposed                     | 3 / 25 (12.00%) | 1 / 12 (8.33%) | 1 / 15 (6.67%) |
| occurrences (all)                               | 3               | 1              | 1              |
| Perioral dermatitis                             |                 |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%)  | 0 / 12 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all)                               | 0               | 0              | 2              |
| Rosacea                                         |                 |                |                |
| subjects affected / exposed                     | 2 / 25 (8.00%)  | 1 / 12 (8.33%) | 1 / 15 (6.67%) |
| occurrences (all)                               | 2               | 1              | 1              |
| Seborrhoeic dermatitis                          |                 |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%)  | 1 / 12 (8.33%) | 0 / 15 (0.00%) |
| occurrences (all)                               | 0               | 1              | 0              |
| Skin mass                                       |                 |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%)  | 0 / 12 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all)                               | 0               | 0              | 0              |
| Trichorrhexis                                   |                 |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%)  | 1 / 12 (8.33%) | 0 / 15 (0.00%) |
| occurrences (all)                               | 0               | 1              | 0              |
| Renal and urinary disorders                     |                 |                |                |
| Dysuria                                         |                 |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%)  | 0 / 12 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all)                               | 0               | 0              | 1              |
| Pollakiuria                                     |                 |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%)  | 0 / 12 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all)                               | 0               | 0              | 1              |
| Urinary incontinence                            |                 |                |                |
| subjects affected / exposed                     | 0 / 25 (0.00%)  | 1 / 12 (8.33%) | 0 / 15 (0.00%) |
| occurrences (all)                               | 0               | 1              | 0              |
| Musculoskeletal and connective tissue disorders |                 |                |                |
| Back pain                                       |                 |                |                |
| subjects affected / exposed                     | 4 / 25 (16.00%) | 1 / 12 (8.33%) | 0 / 15 (0.00%) |
| occurrences (all)                               | 4               | 1              | 0              |
| Myalgia                                         |                 |                |                |

|                             |                 |                 |                 |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 25 (4.00%)  | 0 / 12 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)           | 1               | 0               | 0               |
| Pain in extremity           |                 |                 |                 |
| subjects affected / exposed | 1 / 25 (4.00%)  | 0 / 12 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)           | 1               | 0               | 0               |
| Pain in jaw                 |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 1 / 12 (8.33%)  | 0 / 15 (0.00%)  |
| occurrences (all)           | 0               | 1               | 0               |
| Spinal pain                 |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 0 / 12 (0.00%)  | 1 / 15 (6.67%)  |
| occurrences (all)           | 0               | 0               | 1               |
| Infections and infestations |                 |                 |                 |
| Asymptomatic bacteriuria    |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 0 / 12 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)           | 0               | 0               | 0               |
| Cellulitis                  |                 |                 |                 |
| subjects affected / exposed | 1 / 25 (4.00%)  | 1 / 12 (8.33%)  | 0 / 15 (0.00%)  |
| occurrences (all)           | 2               | 1               | 0               |
| COVID-19                    |                 |                 |                 |
| subjects affected / exposed | 3 / 25 (12.00%) | 2 / 12 (16.67%) | 1 / 15 (6.67%)  |
| occurrences (all)           | 3               | 2               | 1               |
| Bronchitis                  |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 2 / 12 (16.67%) | 2 / 15 (13.33%) |
| occurrences (all)           | 0               | 2               | 2               |
| Cystitis                    |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 1 / 12 (8.33%)  | 0 / 15 (0.00%)  |
| occurrences (all)           | 0               | 1               | 0               |
| Eyelid folliculitis         |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 1 / 12 (8.33%)  | 0 / 15 (0.00%)  |
| occurrences (all)           | 0               | 1               | 0               |
| Folliculitis                |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 0 / 12 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)           | 0               | 0               | 0               |
| Gastroenteritis             |                 |                 |                 |
| subjects affected / exposed | 1 / 25 (4.00%)  | 0 / 12 (0.00%)  | 1 / 15 (6.67%)  |
| occurrences (all)           | 1               | 0               | 1               |

|                             |                 |                 |                 |
|-----------------------------|-----------------|-----------------|-----------------|
| Gastrointestinal infection  |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 1 / 12 (8.33%)  | 1 / 15 (6.67%)  |
| occurrences (all)           | 0               | 1               | 1               |
| Herpes zoster               |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 0 / 12 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)           | 0               | 0               | 0               |
| Herpes simplex              |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 0 / 12 (0.00%)  | 1 / 15 (6.67%)  |
| occurrences (all)           | 0               | 0               | 1               |
| Influenza                   |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 1 / 12 (8.33%)  | 1 / 15 (6.67%)  |
| occurrences (all)           | 0               | 1               | 1               |
| Nasopharyngitis             |                 |                 |                 |
| subjects affected / exposed | 3 / 25 (12.00%) | 2 / 12 (16.67%) | 4 / 15 (26.67%) |
| occurrences (all)           | 5               | 2               | 4               |
| Otitis externa              |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 0 / 12 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)           | 0               | 0               | 0               |
| Oral herpes                 |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 0 / 12 (0.00%)  | 1 / 15 (6.67%)  |
| occurrences (all)           | 0               | 0               | 1               |
| Oral candidiasis            |                 |                 |                 |
| subjects affected / exposed | 1 / 25 (4.00%)  | 1 / 12 (8.33%)  | 0 / 15 (0.00%)  |
| occurrences (all)           | 1               | 1               | 0               |
| Pneumonia                   |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 0 / 12 (0.00%)  | 1 / 15 (6.67%)  |
| occurrences (all)           | 0               | 0               | 1               |
| Pulpitis dental             |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 0 / 12 (0.00%)  | 2 / 15 (13.33%) |
| occurrences (all)           | 0               | 0               | 2               |
| Sinusitis                   |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 0 / 12 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)           | 0               | 0               | 0               |
| Skin candida                |                 |                 |                 |
| subjects affected / exposed | 0 / 25 (0.00%)  | 0 / 12 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)           | 0               | 0               | 0               |

|                                    |                |                |                 |
|------------------------------------|----------------|----------------|-----------------|
| Skin infection                     |                |                |                 |
| subjects affected / exposed        | 1 / 25 (4.00%) | 0 / 12 (0.00%) | 0 / 15 (0.00%)  |
| occurrences (all)                  | 1              | 0              | 0               |
| Tooth infection                    |                |                |                 |
| subjects affected / exposed        | 0 / 25 (0.00%) | 0 / 12 (0.00%) | 0 / 15 (0.00%)  |
| occurrences (all)                  | 0              | 0              | 0               |
| Tonsillitis                        |                |                |                 |
| subjects affected / exposed        | 0 / 25 (0.00%) | 0 / 12 (0.00%) | 1 / 15 (6.67%)  |
| occurrences (all)                  | 0              | 0              | 1               |
| Upper respiratory tract infection  |                |                |                 |
| subjects affected / exposed        | 1 / 25 (4.00%) | 0 / 12 (0.00%) | 0 / 15 (0.00%)  |
| occurrences (all)                  | 1              | 0              | 0               |
| Vulvovaginal mycotic infection     |                |                |                 |
| subjects affected / exposed        | 0 / 25 (0.00%) | 0 / 12 (0.00%) | 1 / 15 (6.67%)  |
| occurrences (all)                  | 0              | 0              | 1               |
| Urinary tract infection            |                |                |                 |
| subjects affected / exposed        | 1 / 25 (4.00%) | 0 / 12 (0.00%) | 1 / 15 (6.67%)  |
| occurrences (all)                  | 1              | 0              | 4               |
| Metabolism and nutrition disorders |                |                |                 |
| Hypercholesterolaemia              |                |                |                 |
| subjects affected / exposed        | 2 / 25 (8.00%) | 0 / 12 (0.00%) | 2 / 15 (13.33%) |
| occurrences (all)                  | 2              | 0              | 2               |
| Hyperkalaemia                      |                |                |                 |
| subjects affected / exposed        | 0 / 25 (0.00%) | 0 / 12 (0.00%) | 1 / 15 (6.67%)  |
| occurrences (all)                  | 0              | 0              | 1               |
| Increased appetite                 |                |                |                 |
| subjects affected / exposed        | 0 / 25 (0.00%) | 0 / 12 (0.00%) | 0 / 15 (0.00%)  |
| occurrences (all)                  | 0              | 0              | 0               |

|                                                       |                    |  |  |
|-------------------------------------------------------|--------------------|--|--|
| <b>Non-serious adverse events</b>                     | Povorcitinib 75 mg |  |  |
| Total subjects affected by non-serious adverse events |                    |  |  |
| subjects affected / exposed                           | 14 / 22 (63.64%)   |  |  |
| Vascular disorders                                    |                    |  |  |
| Hypertension                                          |                    |  |  |
| subjects affected / exposed                           | 1 / 22 (4.55%)     |  |  |
| occurrences (all)                                     | 1                  |  |  |
| General disorders and administration site conditions  |                    |  |  |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  |  |  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|
| <p>Asthenia</p> <p>subjects affected / exposed</p> <p>0 / 22 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>                                                                                                                                                                                                                                                                                                                                                                                               |  |  |  |
| <p>Chest pain</p> <p>subjects affected / exposed</p> <p>0 / 22 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>                                                                                                                                                                                                                                                                                                                                                                                             |  |  |  |
| <p>Fatigue</p> <p>subjects affected / exposed</p> <p>1 / 22 (4.55%)</p> <p>occurrences (all)</p> <p>1</p>                                                                                                                                                                                                                                                                                                                                                                                                |  |  |  |
| <p>Mucosal dryness</p> <p>subjects affected / exposed</p> <p>0 / 22 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>                                                                                                                                                                                                                                                                                                                                                                                        |  |  |  |
| <p>Reproductive system and breast disorders</p> <p>Ejaculation failure</p> <p>subjects affected / exposed</p> <p>0 / 22 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Uterine polyp</p> <p>subjects affected / exposed</p> <p>0 / 22 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>                                                                                                                                                                                                                    |  |  |  |
| <p>Respiratory, thoracic and mediastinal disorders</p> <p>Asthma</p> <p>subjects affected / exposed</p> <p>2 / 22 (9.09%)</p> <p>occurrences (all)</p> <p>2</p> <p>Cough</p> <p>subjects affected / exposed</p> <p>1 / 22 (4.55%)</p> <p>occurrences (all)</p> <p>1</p> <p>Epistaxis</p> <p>subjects affected / exposed</p> <p>0 / 22 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Oropharyngeal pain</p> <p>subjects affected / exposed</p> <p>0 / 22 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> |  |  |  |
| <p>Psychiatric disorders</p> <p>Depression</p> <p>subjects affected / exposed</p> <p>0 / 22 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>                                                                                                                                                                                                                                                                                                                                                                |  |  |  |

|                                                |                 |  |  |
|------------------------------------------------|-----------------|--|--|
| Investigations                                 |                 |  |  |
| Aspergillus test positive                      |                 |  |  |
| subjects affected / exposed                    | 0 / 22 (0.00%)  |  |  |
| occurrences (all)                              | 0               |  |  |
| Blood creatine phosphokinase increased         |                 |  |  |
| subjects affected / exposed                    | 2 / 22 (9.09%)  |  |  |
| occurrences (all)                              | 2               |  |  |
| Haemoglobin decreased                          |                 |  |  |
| subjects affected / exposed                    | 3 / 22 (13.64%) |  |  |
| occurrences (all)                              | 5               |  |  |
| Platelet count decreased                       |                 |  |  |
| subjects affected / exposed                    | 0 / 22 (0.00%)  |  |  |
| occurrences (all)                              | 0               |  |  |
| Weight increased                               |                 |  |  |
| subjects affected / exposed                    | 2 / 22 (9.09%)  |  |  |
| occurrences (all)                              | 2               |  |  |
| Injury, poisoning and procedural complications |                 |  |  |
| Contusion                                      |                 |  |  |
| subjects affected / exposed                    | 1 / 22 (4.55%)  |  |  |
| occurrences (all)                              | 2               |  |  |
| Joint capsule rupture                          |                 |  |  |
| subjects affected / exposed                    | 0 / 22 (0.00%)  |  |  |
| occurrences (all)                              | 0               |  |  |
| Muscle strain                                  |                 |  |  |
| subjects affected / exposed                    | 0 / 22 (0.00%)  |  |  |
| occurrences (all)                              | 0               |  |  |
| Ligament sprain                                |                 |  |  |
| subjects affected / exposed                    | 0 / 22 (0.00%)  |  |  |
| occurrences (all)                              | 0               |  |  |
| Cardiac disorders                              |                 |  |  |
| Sinus tachycardia                              |                 |  |  |
| subjects affected / exposed                    | 0 / 22 (0.00%)  |  |  |
| occurrences (all)                              | 0               |  |  |
| Nervous system disorders                       |                 |  |  |
| Dizziness                                      |                 |  |  |

|                                      |                |  |  |
|--------------------------------------|----------------|--|--|
| subjects affected / exposed          | 2 / 22 (9.09%) |  |  |
| occurrences (all)                    | 2              |  |  |
| Headache                             |                |  |  |
| subjects affected / exposed          | 0 / 22 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Intercostal neuralgia                |                |  |  |
| subjects affected / exposed          | 0 / 22 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Migraine                             |                |  |  |
| subjects affected / exposed          | 0 / 22 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Paraesthesia                         |                |  |  |
| subjects affected / exposed          | 0 / 22 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Polyneuropathy                       |                |  |  |
| subjects affected / exposed          | 0 / 22 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Presyncope                           |                |  |  |
| subjects affected / exposed          | 0 / 22 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Blood and lymphatic system disorders |                |  |  |
| Thrombocytopenia                     |                |  |  |
| subjects affected / exposed          | 0 / 22 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Ear and labyrinth disorders          |                |  |  |
| Ear discomfort                       |                |  |  |
| subjects affected / exposed          | 0 / 22 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Vertigo                              |                |  |  |
| subjects affected / exposed          | 0 / 22 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Eye disorders                        |                |  |  |
| Blepharospasm                        |                |  |  |
| subjects affected / exposed          | 0 / 22 (0.00%) |  |  |
| occurrences (all)                    | 0              |  |  |
| Blepharitis                          |                |  |  |

|                                        |                |  |  |
|----------------------------------------|----------------|--|--|
| subjects affected / exposed            | 0 / 22 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Eye pain                               |                |  |  |
| subjects affected / exposed            | 0 / 22 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Gastrointestinal disorders             |                |  |  |
| Diarrhoea                              |                |  |  |
| subjects affected / exposed            | 0 / 22 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Constipation                           |                |  |  |
| subjects affected / exposed            | 0 / 22 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Dry mouth                              |                |  |  |
| subjects affected / exposed            | 0 / 22 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Dyspepsia                              |                |  |  |
| subjects affected / exposed            | 0 / 22 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Dysphagia                              |                |  |  |
| subjects affected / exposed            | 0 / 22 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Loose tooth                            |                |  |  |
| subjects affected / exposed            | 0 / 22 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Nausea                                 |                |  |  |
| subjects affected / exposed            | 2 / 22 (9.09%) |  |  |
| occurrences (all)                      | 3              |  |  |
| Trichoglossia                          |                |  |  |
| subjects affected / exposed            | 0 / 22 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Skin and subcutaneous tissue disorders |                |  |  |
| Alopecia                               |                |  |  |
| subjects affected / exposed            | 0 / 22 (0.00%) |  |  |
| occurrences (all)                      | 0              |  |  |
| Dermatitis contact                     |                |  |  |

|                             |                |  |  |
|-----------------------------|----------------|--|--|
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Diffuse alopecia            |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Dry skin                    |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Erythema                    |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Hyperhidrosis               |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Lichen myxoedematosus       |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Neurodermatitis             |                |  |  |
| subjects affected / exposed | 2 / 22 (9.09%) |  |  |
| occurrences (all)           | 2              |  |  |
| Perioral dermatitis         |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Rosacea                     |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Seborrhoeic dermatitis      |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Skin mass                   |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Trichorrhexis               |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Renal and urinary disorders |                |  |  |

|                                                 |                |  |  |
|-------------------------------------------------|----------------|--|--|
| Dysuria                                         |                |  |  |
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Pollakiuria                                     |                |  |  |
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Urinary incontinence                            |                |  |  |
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Musculoskeletal and connective tissue disorders |                |  |  |
| Back pain                                       |                |  |  |
| subjects affected / exposed                     | 2 / 22 (9.09%) |  |  |
| occurrences (all)                               | 2              |  |  |
| Myalgia                                         |                |  |  |
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Pain in extremity                               |                |  |  |
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Pain in jaw                                     |                |  |  |
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Spinal pain                                     |                |  |  |
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Infections and infestations                     |                |  |  |
| Asymptomatic bacteriuria                        |                |  |  |
| subjects affected / exposed                     | 0 / 22 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Cellulitis                                      |                |  |  |
| subjects affected / exposed                     | 1 / 22 (4.55%) |  |  |
| occurrences (all)                               | 2              |  |  |
| COVID-19                                        |                |  |  |
| subjects affected / exposed                     | 2 / 22 (9.09%) |  |  |
| occurrences (all)                               | 2              |  |  |
| Bronchitis                                      |                |  |  |

|                             |                |  |  |
|-----------------------------|----------------|--|--|
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Cystitis                    |                |  |  |
| subjects affected / exposed | 1 / 22 (4.55%) |  |  |
| occurrences (all)           | 1              |  |  |
| Eyelid folliculitis         |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Folliculitis                |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Gastroenteritis             |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Gastrointestinal infection  |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Herpes zoster               |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Herpes simplex              |                |  |  |
| subjects affected / exposed | 2 / 22 (9.09%) |  |  |
| occurrences (all)           | 2              |  |  |
| Influenza                   |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Nasopharyngitis             |                |  |  |
| subjects affected / exposed | 2 / 22 (9.09%) |  |  |
| occurrences (all)           | 2              |  |  |
| Otitis externa              |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Oral herpes                 |                |  |  |
| subjects affected / exposed | 1 / 22 (4.55%) |  |  |
| occurrences (all)           | 1              |  |  |
| Oral candidiasis            |                |  |  |

|                                    |                |  |  |
|------------------------------------|----------------|--|--|
| subjects affected / exposed        | 0 / 22 (0.00%) |  |  |
| occurrences (all)                  | 0              |  |  |
| Pneumonia                          |                |  |  |
| subjects affected / exposed        | 1 / 22 (4.55%) |  |  |
| occurrences (all)                  | 1              |  |  |
| Pulpitis dental                    |                |  |  |
| subjects affected / exposed        | 1 / 22 (4.55%) |  |  |
| occurrences (all)                  | 1              |  |  |
| Sinusitis                          |                |  |  |
| subjects affected / exposed        | 2 / 22 (9.09%) |  |  |
| occurrences (all)                  | 2              |  |  |
| Skin candida                       |                |  |  |
| subjects affected / exposed        | 0 / 22 (0.00%) |  |  |
| occurrences (all)                  | 0              |  |  |
| Skin infection                     |                |  |  |
| subjects affected / exposed        | 2 / 22 (9.09%) |  |  |
| occurrences (all)                  | 2              |  |  |
| Tooth infection                    |                |  |  |
| subjects affected / exposed        | 0 / 22 (0.00%) |  |  |
| occurrences (all)                  | 0              |  |  |
| Tonsillitis                        |                |  |  |
| subjects affected / exposed        | 0 / 22 (0.00%) |  |  |
| occurrences (all)                  | 0              |  |  |
| Upper respiratory tract infection  |                |  |  |
| subjects affected / exposed        | 0 / 22 (0.00%) |  |  |
| occurrences (all)                  | 0              |  |  |
| Vulvovaginal mycotic infection     |                |  |  |
| subjects affected / exposed        | 0 / 22 (0.00%) |  |  |
| occurrences (all)                  | 0              |  |  |
| Urinary tract infection            |                |  |  |
| subjects affected / exposed        | 2 / 22 (9.09%) |  |  |
| occurrences (all)                  | 2              |  |  |
| Metabolism and nutrition disorders |                |  |  |
| Hypercholesterolaemia              |                |  |  |
| subjects affected / exposed        | 0 / 22 (0.00%) |  |  |
| occurrences (all)                  | 0              |  |  |

|                             |                |  |  |
|-----------------------------|----------------|--|--|
| Hyperkalaemia               |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Increased appetite          |                |  |  |
| subjects affected / exposed | 0 / 22 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date         | Amendment                                                                                                                                                                                                                                                                                                             |
|--------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 12 July 2021 | The primary purpose of the amendment was to change the inclusion criteria associated with the minimum number of nodules, to include a sub-study for itch and sleep monitoring assessment, and to revise the interim analysis.                                                                                         |
| 06 May 2022  | The primary purpose of the amendment was to remove the interim analysis, modify the exclusion criteria associated with estimated glomerular filtration rate; to add clarification on the types of prurigo nodularis lesions being assessed; and to add clarification on the management of creatine kinase elevations. |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported